Disclosures
Faculty Disclosures
| First Name | Last Name | Role | Session Title | Paper Title | Disclosures |
|---|---|---|---|---|---|
| Adam | Lamble | Speaker | Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why? | Have CARs Stalled for Non-B Cell Malignancies? Where Are We, and Where Are We Going? | Nothing to disclose. |
| Adam | Mead | Speaker | JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging | Embryogenesis and Early Mutations in Hematopoietic Stem Cells | Opna - Honoraria; Opna - Research Funding; Synox - Research Funding; Alethiomics - Current equity holder in publicly-traded company; Alethiomics - Honoraria; Alethiomics - Research Funding; CTI - Honoraria; Roche - Research Funding; Galecto - Honoraria; Galecto - Research Funding; Novartis - Honoraria; Novartis - Research Funding; Morphosys - Honoraria; Pfizer - Honoraria; Medialis - Honoraria; Gilead - Honoraria; Sensyn - Honoraria; Sierra Oncology - Honoraria; BMS - Honoraria; BMS - Research Funding; BMS - Consultancy (Includes expert testimony); Mescape - Honoraria; Karyopharm - Honoraria; Abbvie - Honoraria; Abbvie - Consultancy (Includes expert testimony); Incyte - Honoraria; Ionis - Honoraria; GSK - Honoraria; Sierra Oncology - Honoraria; Agios - Honoraria; Agios - Research Funding; MD-Education - Honoraria; Relay Therapeutics - Honoraria |
| Adam J | de Smith | Speaker | Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine | Decoding Bias in Disease Risk: The Role of Ancestry and Genomic Variant Clustering | Nothing to disclose. |
| Aimee | Hildenbrand | Speaker | ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease | Adherence Recommendations for Hydroxyurea for SCD | Nothing to disclose. |
| Akshay | Sharma Jr | Speaker | What's New and Current in the World of Bone Marrow Failure | The Latest on Aplastic Anemia Management | Sangamo Therapeutics - Consultancy (Includes expert testimony); Vindico Medical Education - Honoraria; Sangamo Therapeutics - Consultancy (Includes expert testimony); National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI) - Research Funding; Medexus inc. - Consultancy (Includes expert testimony); BioLineRx - Consultancy (Includes expert testimony); Medexus Inc - Consultancy (Includes expert testimony); BioLineRx - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Consultancy (Includes expert testimony); CRISPR Therapeutics - Research Funding; Vertex Pharmaceuticals - Research Funding; Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Editas Medicine - Consultancy (Includes expert testimony); Blackwood CME - Honoraria; Blackwood CME - Honoraria; Beam Therapeutics - Research Funding; Editas Medicine - Consultancy (Includes expert testimony); Novartis Pharmaceuticals - Research Funding; Magenta Therapeutics - Research Funding |
| Akshay | Sharma Jr | Chair | What's New and Current in the World of Bone Marrow Failure | BioLineRx - Consultancy (Includes expert testimony); Medexus Inc - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Consultancy (Includes expert testimony); BioLineRx - Consultancy (Includes expert testimony); CRISPR Therapeutics - Research Funding; Magenta Therapeutics - Research Funding; Sangamo Therapeutics - Consultancy (Includes expert testimony); Editas Medicine - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Research Funding; Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Vindico Medical Education - Honoraria; Medexus inc. - Consultancy (Includes expert testimony); Blackwood CME - Honoraria; National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI) - Research Funding; Sangamo Therapeutics - Consultancy (Includes expert testimony); Beam Therapeutics - Research Funding; Blackwood CME - Honoraria; Novartis Pharmaceuticals - Research Funding; Editas Medicine - Consultancy (Includes expert testimony) | |
| Alessandra | Balduini | Chair | The Critical Role of Metabolism in Megakaryocyte and Platelet Biology | Nothing to disclose. | |
| Alessandra | Balduini | Co-Chair | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Nothing to disclose. | |
| Alex Francisco | Herrera | Speaker | How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse | How I Incorporate Novel Therapies into Hodgkin Lymphoma Treatment: Frontline vs. Relapse | Bristol Myers Squibb - Research Funding; Bristol Myers Squibb - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Tubulis - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); SeaGen - Consultancy (Includes expert testimony); SeaGen - Research Funding; Genentech, Inc. - Research Funding; Genentech, Inc. - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Kite - Research Funding; Gilead Sciences - Research Funding; Merck - Consultancy (Includes expert testimony); Merck - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); AstraZeneca - Research Funding; Lilly - Research Funding; Karyopharm Therapeutics - Consultancy (Includes expert testimony); City of Hope - Current Employment; AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Adicet Bio - Consultancy (Includes expert testimony) |
| Alexander | Ngwube | Speaker | To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy | Through Gene Therapy | Nothing to disclose. |
| Alexey V. | Danilov | Speaker | Early Faculty Career Development Session | Developing a Productive Research Program (How to Set up a New Laboratory) - Part 2 | beigene - Research Funding; beigene - Consultancy (Includes expert testimony); GenMab - Consultancy (Includes expert testimony); GenMab - Research Funding; Abbvie - Consultancy (Includes expert testimony); Abbvie - Research Funding; Regeneron - Consultancy (Includes expert testimony); Regeneron - Research Funding; MEI - Research Funding; MEI - Consultancy (Includes expert testimony); Merck - Research Funding; Merck - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Lilly - Research Funding; Bristol-Meyers-Squibb - Consultancy (Includes expert testimony); Incyte - Research Funding; Incyte - Consultancy (Includes expert testimony); Astra Zeneca - Research Funding; Astra Zeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Nurix - Research Funding; ADCT - Consultancy (Includes expert testimony) |
| Alexey V. | Danilov | Speaker | Early Faculty Career Development Session | Setting Yourself Up for Sustained Success - Panelist 2 | beigene - Research Funding; beigene - Consultancy (Includes expert testimony); GenMab - Consultancy (Includes expert testimony); GenMab - Research Funding; Abbvie - Consultancy (Includes expert testimony); Abbvie - Research Funding; Regeneron - Consultancy (Includes expert testimony); Regeneron - Research Funding; MEI - Research Funding; MEI - Consultancy (Includes expert testimony); Merck - Research Funding; Merck - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Lilly - Research Funding; Bristol-Meyers-Squibb - Consultancy (Includes expert testimony); Incyte - Research Funding; Incyte - Consultancy (Includes expert testimony); Astra Zeneca - Research Funding; Astra Zeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Nurix - Research Funding; ADCT - Consultancy (Includes expert testimony) |
| Alexis | Leonard | Speaker | To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy | To Gene Therapy | Nothing to disclose. |
| Alexis A. | Thompson | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | 10 Years of Progress: ASH’s Sickle Cell Disease initiatives | NovoNordisk - Research Funding; NovoNordisk - Consultancy (Includes expert testimony); Bluebird Bio - Research Funding; Bluebird Bio - Consultancy (Includes expert testimony); Vertex - Consultancy (Includes expert testimony); Beam - Research Funding; Beam - Consultancy (Includes expert testimony); Editas - Consultancy (Includes expert testimony); Editas - Research Funding; Novartis - Research Funding; Pfizer - Consultancy (Includes expert testimony) |
| Alexis A. | Thompson | Chair | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | NovoNordisk - Research Funding; Beam - Research Funding; NovoNordisk - Consultancy (Includes expert testimony); Editas - Consultancy (Includes expert testimony); Novartis - Research Funding; Vertex - Consultancy (Includes expert testimony); Bluebird Bio - Research Funding; Pfizer - Consultancy (Includes expert testimony); Beam - Consultancy (Includes expert testimony); Editas - Research Funding; Bluebird Bio - Consultancy (Includes expert testimony) | |
| Alice | Ma | Chair | Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery | Nothing to disclose. | |
| Alice Maria | Taylor | Speaker | The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP | Modern Management of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) | Sobi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony) |
| Amy | Pollak | Speaker | Arterial Disease and the Hematologist | Updates in Antithrombotic Therapy in Coronary and Peripheral Artery Disease | Regeneron - Consultancy (Includes expert testimony); Regeneron - Honoraria; Janssen - Honoraria; Janssen - Consultancy (Includes expert testimony) |
| Amy | Shapiro | Chair | Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients | Regeneron - Research Funding; Innovative Hematology, Inc. - Current Employment; Sanofi-Genzyme/Bioverative - Research Funding; Hema Biologics - Consultancy (Includes expert testimony); Kedrion Biopharma - Research Funding; Genentech, Inc/F. Hoffmann-La Roche Ltd - Consultancy (Includes expert testimony); Plasminogen Deficiency Foundation - Honoraria; Sanofi-Genzyme/Bioverative - Consultancy (Includes expert testimony); hC Bioscience - Research Funding; Pfizer - Consultancy (Includes expert testimony); Novo Nordisk - Honoraria; BioMarin - Honoraria; Be Biopharma - Honoraria; Genentech, Inc/F. Hoffmann-La Roche Ltd - Honoraria; Be Biopharma - Consultancy (Includes expert testimony); BioMarin - Consultancy (Includes expert testimony); Hema Biologics - Honoraria; Pfizer - Research Funding; Novo Nordisk Haemophilia Foundation - Honoraria; hC Bioscience - Honoraria; Centessa Pharmaceuticals/ApcinteX - Research Funding; Sanofi-Genzyme/Bioverative - Honoraria; Pharmacocosmos A/S - Research Funding; Novo Nordisk - Research Funding; Novo Nordisk - Consultancy (Includes expert testimony); Kedrion Biopharma - Consultancy (Includes expert testimony); Kedrion Biopharma - Honoraria; Hemab - Consultancy (Includes expert testimony); Genentech, Inc/F. Hoffmann-La Roche Ltd - Research Funding; Hema Biologics - Research Funding; Pfizer - Honoraria; Hemorare - Research Funding; Be Biopharma - Research Funding; Takeda Pharmaceuticals - Research Funding; Hemab - Research Funding; Hemorare - Consultancy (Includes expert testimony) | |
| Anders | Hansen | Speaker | Dissecting Enhancer Function in Hematopoietic Development and Disease | Imaging and Systems Biology Approaches For Studying Enhancer Activity | Nothing to disclose. |
| Andrea | Sitlinger | Speaker | B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders? | Updates in the Management of Newly Diagnosed Chronic Lymphocytic Leukemia | Genmab - Research Funding; DAVA Oncology - Ended employment in the past 24 months; DAVA Oncology - Consultancy (Includes expert testimony); Loxo/Lilly - Research Funding; Beigene - Consultancy (Includes expert testimony) |
| Andrew | Campbell | Speaker | To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy | Thereafter Gene Therapy | NovoNordisk - Research Funding; Pfizer - Research Funding; Pfizer - Consultancy (Includes expert testimony); Agios - Research Funding; Agios - Consultancy (Includes expert testimony); Fulcrum - Consultancy (Includes expert testimony); Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony) |
| Andrew | Davies | Speaker | Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician | High-grade B-Cell Lymphomas: High Difficulties to Diagnose and Treat? | Cellcentric - Research Funding; Incyte - Honoraria; Incyte - Consultancy (Includes expert testimony); MSD - Research Funding; Sobi - Consultancy (Includes expert testimony); Sobi - Honoraria; Roche - Honoraria; Roche - Consultancy (Includes expert testimony); Roche - Research Funding; BMS - Consultancy (Includes expert testimony); BMS - Honoraria; BMS - Research Funding; Abbvie - Consultancy (Includes expert testimony); Abbvie - Honoraria; Genmab - Consultancy (Includes expert testimony); Genmab - Honoraria; JW Therapeutics - Honoraria; AstraZeneca - Consultancy (Includes expert testimony); AstraZeneca - Research Funding; AstraZeneca - Honoraria; Regeneron - Research Funding; Serb - Honoraria; Serb - Consultancy (Includes expert testimony); Kite/Gilead - Honoraria; Kite/Gilead - Research Funding; Johnson and Johnson - Honoraria |
| Andrew | Intlekofer | Speaker | Targeting Cancer Metabolism – Innovative Methods to Translation | Enzyme Hyperactivation to Target Oncometabolism | Nothing to disclose. |
| Andrew | Wei | Speaker | Targeted Therapy for AML (Triplets and More) | Triplet Regimens for All: Genomically Agnostic Approaches to Improve on HMA + VEN in AML? | Abbvie: as an employee of WEHI receives milestone and royalty payments related to the development of Venetoclax - Patents & Royalties; Abbvie - Consultancy (Includes expert testimony); Abbvie - Research Funding |
| Angela | Dispenzieri | Speaker | Monoclonal Gammopathies of Clinical Significance | POEMS: Syndrome Diagnosis, Treatments, and Outcomes | Celgene - Research Funding; Alnylam - Research Funding; ABBVIE - Research Funding; pfizer - Research Funding; Janssen - Research Funding; Janssen - Consultancy (Includes expert testimony); Takeda - Research Funding |
| Ankur | Singh | Speaker | Innovative Models of Lymphoma | Bioengineering Synthetic Lymphoma Models: Advancements in Ex Vivo Systems | Chan Zuckerberg Initiative - Honoraria; Chan Zuckerberg Initiative - Consultancy (Includes expert testimony); Genentech, Inc - Research Funding |
| Ann-Kathrin | Eisfeld | Co-Chair | Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine | Nothing to disclose. | |
| Anthony Michael | Hunter | Speaker | ASH Clinical Practice Guidelines on Myelofibrosis | Myelofibrosis Recommendation Highlights: Next-Generation Sequencing (NGS), Aspirin Therapy, and Iron Chelators | Incyte - Research Funding; Incyte - Consultancy (Includes expert testimony); Sobi - Honoraria; Sobi - Consultancy (Includes expert testimony); Blueprint Medicines - Research Funding; Blueprint Medicines - Consultancy (Includes expert testimony); Blueprint Medicines - Honoraria; Cogent Biosciences - Research Funding; Cogent Biosciences - Consultancy (Includes expert testimony); Ascentage Pharma - Research Funding; Sumitomo - Research Funding; Sumitomo - Research Funding; PharmaEssentia - Research Funding; PharmaEssentia - Consultancy (Includes expert testimony); PharmaEssentia - Honoraria; Shenzen TargetRx - Research Funding; Ascentage Pharma - Research Funding; Shenzen TargetRx - Research Funding; Sierra Oncology - Consultancy (Includes expert testimony); AbbVie, ADC Therapeutics, AstraZeneca, Autolus Therapeutics, AvenCell Therapeutics, BMS, BMS/Juno Therapeutics, Chimeric Therapeutics, CRISPR Therapeutics, Galapagos, Genmab, Gilead, in8bio, Incyte, Iovance Biotherapeutics, Kite/Gilead, Novartis, Sana Biotechnology, Sanofi and Servier - Honoraria; Incyte - Consultancy (Includes expert testimony); Incyte - Research Funding; Syntrix Biosystems - Research Funding; Novartis - Honoraria; Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony); Blueprint Medicines - Research Funding; Blueprint Medicines - Consultancy (Includes expert testimony); Blueprint Medicines - Honoraria; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); GSK - Honoraria; GSK - Honoraria; GSK - Consultancy (Includes expert testimony); Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony); Novartis - Honoraria; Achieve Clinics, Arcellx, Autolus Therapeutics, Bristol Myers Squibb, Chimeric Therapeutics, CRISPR Therapeutics, In8Bio, Iovance Biotherapeutics, Kite/Gilead, Optum Health, Novartis, Sana Biotechnology - Consultancy (Includes expert testimony); Autolus Therapeutics, AvenCell Therapeutics, BMS/Juno Therapeutics, Chimeric Therapeutics, CRISPR Therapeutics, Galapagos, Kite/Gilead, in8bio, Incyte, Iovance Biotherapeutics, Novartis, Sana Biotechnology - Consultancy (Includes expert testimony); Achieve Clinics and in8bio - Current holder of stock options in a privately-held company; Syntrix Biosystems - Research Funding; PharmaEssentia - Honoraria; PharmaEssentia - Research Funding; PharmaEssentia - Consultancy (Includes expert testimony); Karyopharm - Honoraria; Karyopharm - Consultancy (Includes expert testimony); Sobi - Honoraria; Sobi - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Cogent Biosciences - Research Funding; Arcellx, Autolus Therapeutics, BMS, CRISPR Therapeutics, Gilead, Lyell and Novartis - Research Funding |
| Arnaud | Jaccard | Speaker | Monoclonal Gammopathies of Clinical Significance | Monoclonal Related Neuropathies: Diagnosis, Prognosis, and Outcomes | Janssen - Research Funding; Janssen - Honoraria; Janssen - Consultancy (Includes expert testimony); Prothena - Consultancy (Includes expert testimony); Amgen - Honoraria; Sanofi - Research Funding; Pfizer - Honoraria; Celgene - Research Funding; Celgene - Honoraria |
| Ashley | Brown | Speaker | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Clots, Cuts, and Healing: The Dynamic trio of Coagulation, Platelets, and Fibrinolysis | Selsym Biotechnology, Inc. - Divested equity in a private or publicly-traded company in the past 24 months; Selsym Biotechnology, Inc. - Current equity holder in private company; Selsym Biotechnology, Inc. - Consultancy (Includes expert testimony); Selsym Biotechnology, Inc. - Research Funding; Selsym Biotechnology, Inc. - Patents & Royalties |
| Austin G. | Kulasekararaj | Speaker | ASH Clinical Practice Guidelines on Aplastic Anemia | Recommendations for Diagnosis of Aplastic Anemia | Agios, Alexion (AstraZeneca Rare Disease), Amgen, Celgene/Bristol Myers Squibb, Novartis, Pfizer, Roche, Samsung and Sobi - Honoraria; AbbVie, Alexion (AstraZeneca Rare Disease), Celgene/Bristol Myers Squibb, Janssen, Novartis, Novo Nordisk, Pfizer, Roche, Samsung, and Sobi - Consultancy (Includes expert testimony); Pfizer - Current holder of stock options in a privately-held company |
| Austin G. | Kulasekararaj | Chair | Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes | Agios, Alexion (AstraZeneca Rare Disease), Amgen, Celgene/Bristol Myers Squibb, Novartis, Pfizer, Roche, Samsung and Sobi - Honoraria; Pfizer - Current holder of stock options in a privately-held company; AbbVie, Alexion (AstraZeneca Rare Disease), Celgene/Bristol Myers Squibb, Janssen, Novartis, Novo Nordisk, Pfizer, Roche, Samsung, and Sobi - Consultancy (Includes expert testimony) | |
| Bart L | Scott | Speaker | Grassroots Network Lunch | Expanded Advocacy and Fight4Hematology | Geron - Honoraria; Geron - Research Funding; Novartis - Research Funding; Novartis - Honoraria; Novartis - Consultancy (Includes expert testimony); Incyte - Honoraria; Incyte - Consultancy (Includes expert testimony); Alexion - Honoraria; Alexion - Consultancy (Includes expert testimony); Apellis - Honoraria; Apellis - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Celgene - Research Funding; BMS - Research Funding; BMS - Honoraria; BMS - Consultancy (Includes expert testimony) |
| Bart L | Scott | Chair | Grassroots Network Lunch | Celgene - Consultancy (Includes expert testimony); Novartis - Research Funding; BMS - Consultancy (Includes expert testimony); Novartis - Honoraria; Geron - Honoraria; Alexion - Consultancy (Includes expert testimony); Apellis - Honoraria; BMS - Research Funding; Geron - Research Funding; Incyte - Honoraria; Celgene - Research Funding; Alexion - Honoraria; Incyte - Consultancy (Includes expert testimony); BMS - Honoraria; Apellis - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony) | |
| Belinda | Avalos | Chair | E. Donnall Thomas Lecture and Prize | BMJ Best Practice - Patents & Royalties; Juno - Honoraria | |
| Belinda | Avalos | Chair | Ham-Wasserman Lecture | BMJ Best Practice - Patents & Royalties; Juno - Honoraria | |
| Belinda | Avalos | Chair | Presidential Symposium | BMJ Best Practice - Patents & Royalties; Juno - Honoraria | |
| Belinda | Avalos | Co-Chair | ASH-EHA Joint Symposium | BMJ Best Practice - Patents & Royalties; Juno - Honoraria | |
| Benjamin | Ebert | Speaker | Meet The Scientist: Hematopoietic Clones - To Be or Not to Be | Hematopoietic Clones - To Be or Not to Be | Exo Therapeutics - Consultancy (Includes expert testimony); Exo Therapeutics - Current holder of stock options in a privately-held company; Neomorph Inc - Current holder of stock options in a privately-held company; Neomorph Inc - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Big Sur Bio - Current holder of stock options in a privately-held company; Big Sur Bio - Consultancy (Includes expert testimony); Skyhawk - Consultancy (Includes expert testimony); Skyhawk - Current holder of stock options in a privately-held company; Calico - Research Funding; Novartis - Research Funding |
| Benjamin A | Derman | Speaker | Treatment Refinement in Multiple Myeloma | Can I Stop My Treatment, Doctor? Is MRD-Guided Therapy Ready for Prime Time? | GSK - Research Funding; COTA - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Amgen - Research Funding; Gerson Lehrman Group - Consultancy (Includes expert testimony); Canopy - Consultancy (Includes expert testimony); Plexus - Honoraria; BMS - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Guidepoint Global - Consultancy (Includes expert testimony); UChicago Medicine - Current Employment; Multiple Myeloma Research Foundation - Honoraria |
| Benoit | Vingert | Speaker | TRIMming the Immune Response: Cutting-Edge Insights into Transfusion-Related Immunomodulation | Little Secrets: Microparticles in Blood Products as Immune Modulators | Nothing to disclose. |
| Bert | Van der Reijden | Chair | Epigenomic Frontiers in the Diagnosis of Hematological Malignancies | Nothing to disclose. | |
| Bethany | Samuelson Bannow | Speaker | Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery | Pregnancy Management for Patients with Bleeding Disorders | Nothing to disclose. |
| Bin | He | Speaker | Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease | Treat the Pain in My Brain: Understanding Neuromodulation and Technology Enhanced Interventions for Sickle Cell Disease Pain | Nothing to disclose. |
| Birgitte Klug | Albertsen Sr | Speaker | Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New Efficacious Preparations | Asparaginase Hypersensitivity Incidence, Manifestations, and Management | Servier - Consultancy (Includes expert testimony) |
| Brady | Stein | Chair | ASH Clinical Practice Guidelines on Myelofibrosis | Nothing to disclose. | |
| Brenda M | Sandmaier | Speaker | New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) | New Age HCT Conditioning Regimens: What Works and Why? | Actinium Pharmaceutical - Patents & Royalties; Orca Bio - Consultancy (Includes expert testimony) |
| Brooke | Boring | Speaker | ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns | Advocacy at the federal and state level and how practitioners can get engaged | Nothing to disclose. |
| Callie | Berkowitz | Speaker | Bleeding Disorder of Unknown Cause—What Do We Know? | Buckle Up! Managing Surgery in Patients with Bleeding Disorder of Unknown Cause (BDUC) | National Bleeding Disorder Foundation - Takeda - Research Funding |
| Camila | Masias | Speaker | Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults | What treatment should be given to adults with primary ITP who require therapy beyond steroids? Recommendations from the ASH Guidelines | Sanofi - Consultancy (Includes expert testimony); Sanofi - Honoraria; Argenx - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony) |
| Catherine | Chunda-Liyoka | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Consortium on Newborn Screening in Africa – Diagnostic to Community Based Efforts | Nothing to disclose. |
| Catherine | Chunda-Liyoka | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Nothing to disclose. | |
| Catherine | Hayward | Speaker | Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders | When It’s Not Glanzmann Thrombasthenia or Bernard Soulier Syndrome: Diagnosing Other Qualitative Platelet Disorders | UpToDate - Patents & Royalties; Stago - Consultancy (Includes expert testimony); Werfen - Consultancy (Includes expert testimony) |
| Catherine | Smith | Speaker | Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias | Multi-omic Analysis Reveals the Heterogeneity and Stem Cell Origin of Acute Leukemia of Ambiguous Lineage/Mixed Phenotype Acute Leukemia | Nothing to disclose. |
| Catherine | Smith | Co-Chair | Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias | Nothing to disclose. | |
| Cesar | Rodriguez Valdes | Speaker | Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit | Transplant in Myeloma: What is its Role? | Janssen, Takeda, Bristol Myers Squibb, Amgen, and Karyopharm Therapeutics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Janssen - Current equity holder in private company; Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony) |
| Cesar | Rodriguez Valdes | Speaker | Treating Fairly Rounds Lunch | Healthcare Access to Non-English Speaking Populations - Presenter 2 | Janssen, Takeda, Bristol Myers Squibb, Amgen, and Karyopharm Therapeutics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Janssen - Current equity holder in private company; Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony) |
| Chiara | Bonini | Speaker | Ham-Wasserman Lecture | Gene Transfer and Genome Editing of T Cells for Cancer Immunotherapy | 2seventybio - Patents & Royalties; Gentibio - Consultancy (Includes expert testimony); Gentibio - Research Funding; Chroma - Consultancy (Includes expert testimony); SmartImmune - Research Funding; SmartImmune - Consultancy (Includes expert testimony); Miltenyi - Patents & Royalties; Avencell - Patents & Royalties; Alia - Consultancy (Includes expert testimony); Intellia Therapeutics - Consultancy (Includes expert testimony) |
| Christopher | Patriquin | Speaker | Complementopathies: Modern Diagnosis and Management | The Varieties of Therapeutic Experience: Navigating Treatment Options for Patients with PNH | Amgen - Consultancy (Includes expert testimony); Amgen - Honoraria; Novartis - Consultancy (Includes expert testimony); Novartis - Honoraria; Sobi - Consultancy (Includes expert testimony); Sobi - Honoraria; Regeneron - Honoraria; Regeneron - Consultancy (Includes expert testimony); Roche - Honoraria; Roche - Consultancy (Includes expert testimony); Alexion - Honoraria; Alexion - Consultancy (Includes expert testimony) |
| Christopher | Patriquin | Chair | Complementopathies: Modern Diagnosis and Management | Roche - Honoraria; Sobi - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Sobi - Honoraria; Roche - Consultancy (Includes expert testimony); Amgen - Honoraria; Regeneron - Honoraria; Regeneron - Consultancy (Includes expert testimony); Alexion - Honoraria; Alexion - Consultancy (Includes expert testimony); Novartis - Honoraria; Novartis - Consultancy (Includes expert testimony) | |
| Clara | Chamba | Speaker | Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally | Burkitt Lymphoma Research in Africa: Overcoming Challenges and Unlocking Translational Potential | Nothing to disclose. |
| Clara | Chamba | Co-Chair | Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally | Nothing to disclose. | |
| Claudia | Waskow | Speaker | Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease | Highlighting the Role of Fetal Blood Cells In Shaping the Life-Long Blood System | Nothing to disclose. |
| Clementine | Sarkozy | Speaker | Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician | All Shades of Gray in the Mediastinum: Do We Have Bright Ideas About How to Diagnose and Treat Mediastinal Gray Zone Lymphoma in the Era of Targeted Agents? | BMS - Honoraria; Beigene - Honoraria; Astra-Zeneca - Honoraria; Roche - Honoraria; Abbvie - Honoraria |
| Colleen | Annesley | Speaker | How I Treat Isolated CNS Relapse of B-ALL in the Era of Immunotherapy | How I Treat Isolated CNS Relapse of B-ALL in the Era of Immunotherapy | Nothing to disclose. |
| Courtney | Jones | Speaker | Early Faculty Career Development Session | Developing a Productive Research Program (How to Set up a New Laboratory) - Part 1 | Nothing to disclose. |
| Courtney | Jones | Speaker | Early Faculty Career Development Session | Setting Yourself Up for Sustained Success - Panelist 1 | Nothing to disclose. |
| Craig | Byersdorfer | Chair | Strategies To Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cellular Therapies | Nothing to disclose. | |
| Daniel | Bauer | Speaker | Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy | Preclinical Development of Gene Editing Approaches for Hemoglobin Disorders | Nothing to disclose. |
| David T. | Teachey | Speaker | Genomics in Pediatric Acute Leukemia Risk Stratification | The Genomics of Pediatric T-ALL | Sobi - Consultancy (Includes expert testimony); BEAM Therapeutics - Research Funding; Syndax - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); J&J Innovation - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Neoimmune Tech - Research Funding; Amgen - Research Funding; Pfizer - Consultancy (Includes expert testimony); CART - Patents & Royalties; Jazz - Consultancy (Includes expert testimony) |
| David T. | Teachey | Chair | Genomics in Pediatric Acute Leukemia Risk Stratification | Syndax - Consultancy (Includes expert testimony); CART - Patents & Royalties; Amgen - Research Funding; Abbvie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Neoimmune Tech - Research Funding; Sobi - Consultancy (Includes expert testimony); J&J Innovation - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); BEAM Therapeutics - Research Funding; Jazz - Consultancy (Includes expert testimony) | |
| Deena | Iskander | Speaker | Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes | The Role of Ribosome Dysregulation in Erythropoiesis | Nothing to disclose. |
| Dominique | Bonnet | Speaker | New Frontiers in Neutrophil Biology | Effect on Clonal Hematopoiesis Associated Mutations on Neutrophil Function | Nothing to disclose. |
| Donald | Arnold | Speaker | Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery | A Practical Approach to Immune Thrombocytopenia in Pregnancy | Novartis - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Platelet Disorders Support Association – medical advisor (unpaid) - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); UptoDate - Patents & Royalties; Medison - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); Canadian Blood Services - Research Funding; Paradigm - Consultancy (Includes expert testimony); Public Health Agency of Canada - Research Funding; Canadian Institutes of Health Research - Research Funding |
| Donald | Arnold | Speaker | Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults | Considerations on the Role of Splenectomy and Switching TPOs After Treatment Failure | Novartis - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Platelet Disorders Support Association – medical advisor (unpaid) - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); UptoDate - Patents & Royalties; Medison - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); Canadian Blood Services - Research Funding; Paradigm - Consultancy (Includes expert testimony); Public Health Agency of Canada - Research Funding; Canadian Institutes of Health Research - Research Funding |
| Doris K. | Hansen | Speaker | Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma | CAR T-cell and Bispecific Antibodies in the Management of Multiple Myeloma | Karyopharm - Consultancy (Includes expert testimony); Karyopharm - Research Funding; Kite Pharma - Research Funding; Kite Pharma - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Janssen - Research Funding; Legend Biotech - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); BMS - Research Funding; Adaptive Biotechnologies - Research Funding |
| Douglas | Cines Sr | Chair | Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults | Novartis - Honoraria; Sanofi - Honoraria | |
| Douglas | Tremblay | Speaker | ASH Clinical Practice Guidelines on Myelofibrosis | Jak Inhibitors in Myelofibrosis: Recommendations for Different Risk Profiles, Symptoms, and Treatment History | Gilead - Research Funding; Sobi - Research Funding; Sobi - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); Cogent - Research Funding; Geron - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony) |
| Eirini | Trompouki | Speaker | Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny | Preventing Fires: Targeting Strategies to Mitigate Clonal Evolution | Nothing to disclose. |
| Elvin | Wagenblast | Speaker | Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease | Recent Insights Into the Pathophysiology of Hematologic Disease With Fetal Origins | Nothing to disclose. |
| Emanuele | Angelucci | Speaker | Biology-Based Management of Iron Toxicity and Overload in Hematology Practice | Iron Toxicity and Hemopoietic Cell Transplantation: Do We Understand Why Iron Affects Transplant Outcome? | BMS - Honoraria; Vertex - Honoraria; Sanofi - Honoraria; Johnson & Johnson - Honoraria; Menarini-Stemline - Consultancy (Includes expert testimony) |
| Emily | Gwyer Findlay | Speaker | New Frontiers in Neutrophil Biology | Neutrophils in Tumor Immunity | Nothing to disclose. |
| Emily | Mackler | Speaker | ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns | Combatting drug shortages with drug repository programs | Nothing to disclose. |
| Emma | Groarke | Speaker | ASH Clinical Practice Guidelines on Aplastic Anemia | Recommendations for IST and medical management of Aplastic Anemia | Nothing to disclose. |
| Enrico | Di Cera | Speaker | Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins | Unveiling the Hemostasis Interactome: A Structure-Guided Discovery of Blood's Hidden Secrets | Nothing to disclose. |
| Eric | Pietras | Speaker | Presidential Symposium | Role of the Microenvironment in Leukemogenesis | Nothing to disclose. |
| Eunice Sue | Wang | Speaker | Targeted Therapy for AML (Triplets and More) | The Promise of Menin Inhibitors: From Approval to Triplet Regimens | Kite - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Schrodinger - Consultancy (Includes expert testimony); Ryvu - Consultancy (Includes expert testimony); Blueprint - Consultancy (Includes expert testimony); Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Dava Oncology - Honoraria; Takeda - Consultancy (Includes expert testimony); Kura - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); UpToDate (Section Editor) - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Astellas - Honoraria; Daiichi Sankyo - Consultancy (Includes expert testimony) |
| Florence | Nguyen-Khac | Speaker | Epigenomic Frontiers in the Diagnosis of Hematological Malignancies | Chromatin-Based Diagnosis in Lymphocytic Leukemia | Nothing to disclose. |
| France | Pirenne | Chair | TRIMming the Immune Response: Cutting-Edge Insights into Transfusion-Related Immunomodulation | Nothing to disclose. | |
| Franck | Morschhauser | Speaker | Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Selecting the Best Treatment Approach and Optimizing Sequencing Strategies in Large B-cell Lymphoma | Roche, BMS, Gilead, AbbVie, Janssen, Takeda - Consultancy (Includes expert testimony); Miltenyi, AstraZeneca - Honoraria |
| Francois-Xavier | Mahon | Speaker | The Changing Face of Chronic Myelogenous Leukemia | Can I Stop Taking My TKI Yet? | Nothing to disclose. |
| Freda | Passam | Speaker | Arterial Disease and the Hematologist | Managing Patients with a History of Arterial Disease and New Venous Thromboembolism | AstraZeneca - Honoraria |
| Gabriela Soriano | Hobbs | Chair | The Changing Face of Chronic Myelogenous Leukemia | Merck & Co., Inc. - Consultancy (Includes expert testimony); Merck & Co., Inc. - Research Funding; Incyte - Research Funding; GSK - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); cogent - Consultancy (Includes expert testimony); novartis - Consultancy (Includes expert testimony) | |
| Gaurav | Goyal | Speaker | Down the Rabbit Hole: An Update on Histiocytic Disorders | The Xanthogranuloma Family of Histiocytic Neoplasms in the Molecular Era: Erdheim-Chester Disease and Beyond | Electra Therapeutics - Honoraria; Sobi - Honoraria; Pharmassentia - Honoraria; Recordati - Consultancy (Includes expert testimony) |
| Gaurav | Goyal | Chair | Down the Rabbit Hole: An Update on Histiocytic Disorders | Sobi - Honoraria; Recordati - Consultancy (Includes expert testimony); Electra Therapeutics - Honoraria; Pharmassentia - Honoraria | |
| Giuliana | Ferrari Jr | Speaker | Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy | Developing Gene Therapy Approaches for Treating Hemoglobin Disorders | Nothing to disclose. |
| Giuseppe | Saglio | Co-Chair | JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia | Novartis - Consultancy (Includes expert testimony); Enliven - Consultancy (Includes expert testimony); Ascentage - Honoraria; Novartis - Honoraria; Ascentage - Consultancy (Includes expert testimony); .Hikma - Consultancy (Includes expert testimony); .Hikma - Honoraria; Enliven - Honoraria | |
| Grant | Challen | Speaker | JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging | Genetic-Epigenetic Regulators Providing a Competitive Advantage to HSCs | Incyte - Research Funding; Incyte - Consultancy (Includes expert testimony); Incyte - Honoraria; Ajax Therapeutics - Consultancy (Includes expert testimony); ReNAgade Therapeutics Management - Consultancy (Includes expert testimony); Pairidex - Current equity holder in private company; Pairidex - Patents & Royalties; Atavistik Bio - Research Funding; Atavistik Bio - Consultancy (Includes expert testimony) |
| Guy | Young | Speaker | Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients | Deconstructing Gene Therapy in Hemophilia for the Clinician | Alnylam, ASC Biotherapeutics, Bayer, BioMarin, CSL Behring, Genentech/Roche, Hema Biologics, Hemab, Novo Nordisk, Octapharma, Pfizer, Sanofi Genzyme, Spark, and Takeda - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Novo Nordisk - Honoraria; Sanofi - Research Funding; Genentech/Roche - Honoraria; Genentech/Roche - Consultancy (Includes expert testimony); ASC Biotherapeutics - Consultancy (Includes expert testimony); BioMarin - Honoraria; BioMarin - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Pfizer - Honoraria; Spark - Honoraria; Spark - Consultancy (Includes expert testimony); HEMA Biologics/LFB - Consultancy (Includes expert testimony); HEMA Biologics/LFB - Honoraria; Sanofi - Consultancy (Includes expert testimony); Sanofi - Honoraria; Sanofi - Research Funding |
| Heather | Leitch | Speaker | Biology-Based Management of Iron Toxicity and Overload in Hematology Practice | Management of Iron Overload in Adult Myelodysplastic Syndrome | Taiho - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Fibrogen - Research Funding; Pharmacocosmos - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Research Funding; Forma - Research Funding |
| Heather J. | Landau | Speaker | Monoclonal Gammopathies of Clinical Significance | Monoclonal Gammopathy of Renal Significance from a Hematologic Perspective | Karyopharm Therapeutics Inc. - Consultancy (Includes expert testimony); Karyopharm Therapeutics Inc. - Honoraria; Prothena - Research Funding; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Nexcella - Research Funding; Nexcella - Consultancy (Includes expert testimony); Nexcella - Honoraria; Bristol Myers Squibb - Honoraria; Bristol Myers Squibb - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Research Funding; Alexion Pharmaceuticals - Honoraria; AbbVie - Honoraria; AbbVie - Research Funding; AbbVie - Consultancy (Includes expert testimony); Arcellx - Honoraria; Arcellx - Consultancy (Includes expert testimony); Protego - Research Funding |
| Hetty | Carraway | Speaker | What's New and Current in the World of Bone Marrow Failure | Updates on Low/Intermediate-Risk MDS | ASTEX - Research Funding; Syndax - Research Funding; Syndax - Consultancy (Includes expert testimony); Jazz - Consultancy (Includes expert testimony); AbbVie - Research Funding; Servier - Consultancy (Includes expert testimony); Servier - Honoraria; Novartis - Consultancy (Includes expert testimony); Novartis - Honoraria; Oncoverity - Consultancy (Includes expert testimony); Oncoverity - Honoraria; Celgene - Research Funding; Rigel - Consultancy (Includes expert testimony); Rigel - Honoraria; Agios - Honoraria; Agios - Consultancy (Includes expert testimony); Daiichi - Honoraria; Daiichi - Consultancy (Includes expert testimony); Stemline - Honoraria; Stemline - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); BMS - Honoraria; CTI Biopharma - Consultancy (Includes expert testimony); CTI Biopharma - Honoraria; Kura - Honoraria; Kura - Consultancy (Includes expert testimony); Takeda - Honoraria; Takeda - Research Funding |
| Hetty | Carraway | Chair | Early Faculty Career Development Session | Rigel - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Daiichi - Honoraria; AbbVie - Research Funding; Takeda - Honoraria; Stemline - Honoraria; Rigel - Honoraria; ASTEX - Research Funding; Jazz - Consultancy (Includes expert testimony); Kura - Honoraria; Syndax - Research Funding; Oncoverity - Honoraria; Oncoverity - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); Servier - Honoraria; CTI Biopharma - Consultancy (Includes expert testimony); CTI Biopharma - Honoraria; Daiichi - Consultancy (Includes expert testimony); Celgene - Research Funding; Syndax - Consultancy (Includes expert testimony); Takeda - Research Funding; Agios - Honoraria; Novartis - Honoraria; Kura - Consultancy (Includes expert testimony); BMS - Honoraria | |
| Hyacinth | Hyacinth | Chair | Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease | Nothing to disclose. | |
| Imo | Akpan | Speaker | ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia | Ferritin, TSAT, and how low is too low: Diagnosis of iron deficiency in adults | Pharmacosmos Therapeutics Inc. - Consultancy (Includes expert testimony); Pharmacosmos Therapeutics Inc. - Honoraria |
| Ingo | Ringshausen | Chair | JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging | Nothing to disclose. | |
| Ingrid | Pabinger Sr | Speaker | Bleeding Disorder of Unknown Cause—What Do We Know? | Predictors for Future Bleeding in Bleeding Disorder of Unknown Cause | BMS/Pfizer - Honoraria; Sobi - Honoraria; CSL Behring - Honoraria; CSL Behring - Consultancy (Includes expert testimony); Roche - Research Funding; Bayer - Honoraria; Novo Nordisk - Honoraria; Takeda - Honoraria |
| Jacquelyn | Powers | Chair | ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia | Nothing to disclose. | |
| Jahnavi | Gollamudi | Speaker | Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease | It Refuses to Leave: The Challenging Bone Pain in Sickle Cell Disease | Nothing to disclose. |
| Jane | Churpek | Speaker | Presidential Symposium | Germline Predisposition for Myeloid Neoplasms | UpToDate,Inc - Honoraria |
| Jane | Hankins | Speaker | ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease | Dosing Recommendations for Hydroxyurea for SCD | UpToDate - Patents & Royalties; University of Tennessee-UTHSC - Honoraria; NCI - Research Funding; CDC - Research Funding |
| Jeffrey C | Rathmell | Speaker | Targeting Cancer Metabolism – Innovative Methods to Translation | Metabolic Sources of Immune Cell Dysfunction | Sitryx Therapeutics - Consultancy (Includes expert testimony) |
| Jennifer L. | Crombie | Speaker | Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Could Treatment Modification Based on Early Response Assessment Improve Results in DLBCL? | Merck, Genentech/Roche, Abbvie, Bayer - Research Funding; Genentech/Roche, Genmab/Abbvie, Regeneron, Kite, Lilly, Novartis, ADC Therapeutics, BMS - Consultancy (Includes expert testimony) |
| Jesse | Boehm Jr | Speaker | Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine | Moving Towards Precision Medicine: Influence of Germline and Ancestry on Preclinical Target Discovery | Nothing to disclose. |
| Jesse | Rowley | Speaker | The Critical Role of Metabolism in Megakaryocyte and Platelet Biology | Mitochondria Morphology, Function and Platelet Activation Responses | Nothing to disclose. |
| Jessica Kaplan | Altman | Speaker | How I Incorporate Mutational Profiling into Treatment of AML: Considerations Based on Age, Complex Cytogenetics, and Other Clinical Factors | How I Incorporate Mutational Profiling into Treatment of AML: Considerations Based on Age, Complex Cytogenetics, and Other Clinical Factors | Curio - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Onviv - Honoraria; Onviv - Consultancy (Includes expert testimony); MD Education - Honoraria; Daiichi Sankyo - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Omeros - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); Astellas - Honoraria; Astellas - Research Funding; Astellas - Consultancy (Includes expert testimony); Kura Oncology - Research Funding; Kura Oncology - Consultancy (Includes expert testimony); HMP Global - Honoraria; VJ Heme Onc - Honoraria; Dark Blue Therapeutics - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); PeerView - Honoraria |
| Jessica Kaplan | Altman | Speaker | Targeted Therapy for AML (Triplets and More) | Targeted Triplet Therapies incorporating FLT3 or IDH Inhibitors: Ready for Prime Time? | Curio - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Onviv - Honoraria; Onviv - Consultancy (Includes expert testimony); MD Education - Honoraria; Daiichi Sankyo - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Omeros - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); Astellas - Honoraria; Astellas - Research Funding; Astellas - Consultancy (Includes expert testimony); Kura Oncology - Research Funding; Kura Oncology - Consultancy (Includes expert testimony); HMP Global - Honoraria; VJ Heme Onc - Honoraria; Dark Blue Therapeutics - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); PeerView - Honoraria |
| Jessica Kaplan | Altman | Chair | Targeted Therapy for AML (Triplets and More) | Onviv - Honoraria; Astellas - Honoraria; Abbvie - Consultancy (Includes expert testimony); Dark Blue Therapeutics - Consultancy (Includes expert testimony); PeerView - Honoraria; Syndax - Consultancy (Includes expert testimony); Onviv - Consultancy (Includes expert testimony); Omeros - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Kura Oncology - Research Funding; HMP Global - Honoraria; Astellas - Research Funding; MD Education - Honoraria; Astellas - Consultancy (Includes expert testimony); Curio - Consultancy (Includes expert testimony); Kura Oncology - Consultancy (Includes expert testimony); VJ Heme Onc - Honoraria; Aptitude Health - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony) | |
| Jesus | San-Miguel Sr | Chair | Treatment Refinement in Multiple Myeloma | On behalf of my Institution: Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, SecuraBio and Gilead-Kite - Consultancy (Includes expert testimony); On behalf of my Institution: Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, SecuraBio and Gilead-Kite - Honoraria | |
| Jian | Xu | Chair | Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy | Agios Pharmaceuticals - Consultancy (Includes expert testimony) | |
| John | Koreth | Speaker | New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) | New Age GVHD Prophylaxis Regimens: What Works for What Donor and Why | Equillium Biotherapeutics - Consultancy (Includes expert testimony); Equillium Biotherapeutics - Research Funding; Tr1X Bio - Consultancy (Includes expert testimony); Tr1X Bio - Research Funding; Miltenyi GmbH - Research Funding; BMS Inc - Research Funding; Cugene Inc - Consultancy (Includes expert testimony); Biopharm Communications LLC - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Mallinckrodt Inc - Consultancy (Includes expert testimony); Iovance Inc - Research Funding |
| John F. | DiPersio | Speaker | Presidential Symposium | Novel Therapeutic Approaches | RiverVest - Consultancy (Includes expert testimony); Wugen - Patents & Royalties; Wugen - Research Funding; Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Magenta Therapeutics - Patents & Royalties; MacroGenics - Research Funding; BioLineRX - Consultancy (Includes expert testimony); BioLineRX - Research Funding |
| Jonathan L | Kaufman | Speaker | Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit | What is the Best Induction for Myeloma for the FIT patient? | Ascentage - Honoraria; Ascentage - Consultancy (Includes expert testimony); Heidelberg Pharma AB - Research Funding; Kite Pharma, Inc - Research Funding; Nexcella, Inc. - Research Funding; BMS - Honoraria; BMS - Consultancy (Includes expert testimony); BMS - Research Funding; Poseida - Research Funding; Genentech - Research Funding; Genentech - Consultancy (Includes expert testimony); Beigene - Research Funding; Takeda - Research Funding; Amgen - Research Funding; Novartis - Research Funding; GlaxoSmithKline - Research Funding; Fortis Therapeutics - Research Funding; Pfizer - Research Funding; Janssen - Research Funding; Genmab - Research Funding; Abbvie - Research Funding; Sebia - Consultancy (Includes expert testimony); Sebia - Honoraria; Sanofi - Consultancy (Includes expert testimony); Sanofi - Honoraria |
| Jorge | Cortes | Speaker | The Changing Face of Chronic Myelogenous Leukemia | Frontline Treatment Selection for CML in 2025 | Takeda - Consultancy (Includes expert testimony); Cyto Agents - Research Funding; Kuro Oncology - Consultancy (Includes expert testimony); Kuro Oncology - Research Funding; Syndax - Consultancy (Includes expert testimony); Jenssen - Consultancy (Includes expert testimony); Tern Pharma - Research Funding; Tern Pharma - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Ascentage - Research Funding; Biopath Holdings - Consultancy (Includes expert testimony); Biopath Holdings - Research Funding; Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony); BMS - Research Funding; Pfizer - Consultancy (Includes expert testimony); Enliven - Consultancy (Includes expert testimony); Sun Pharma - Research Funding; Sun Pharma - Consultancy (Includes expert testimony) |
| Jorge J | Castillo | Speaker | Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician | When Immature Plasma Cells Form Lymphoma: How to Improve on Diagnostics and Treatment of Plasmablastic Lymphoma? | Loxo - Research Funding; Loxo - Consultancy (Includes expert testimony); Cellectar - Consultancy (Includes expert testimony); Cellectar - Research Funding; Pharmacyclics - Research Funding; Pharmacyclics - Consultancy (Includes expert testimony); Schrodinger - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); AbbVie - Research Funding; Janssen - Consultancy (Includes expert testimony); BeOne - Research Funding; BeOne - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony) |
| Jori | May | Speaker | How I Navigate Arterial Thrombosis: A Hematologist's Perspective | How I Navigate Arterial Thrombosis: A Hematologist's Perspective | Nothing to disclose. |
| Jori | May | Chair | Arterial Disease and the Hematologist | Nothing to disclose. | |
| Joseph | Mikhael | Chair | Monoclonal Gammopathies of Clinical Significance | Sanofi - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony) | |
| Julie | Jaffray | Chair | CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias | Boehringer-Ingelheim - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony) | |
| Julie-An Marie | Talano | Speaker | New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) | Donor Selection, Graft Engineering and Dosing Oh My! | Nothing to disclose. |
| Julie-An Marie | Talano | Chair | New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) | Nothing to disclose. | |
| Jurgen | Kuball Jr | Speaker | Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why? | Post-Transplant Cells for the Win? DLI and Adoptive Cell Therapy To Eradicate MRD | Gadeta Founders BV - Patents & Royalties; Miltenyi Biotech - Research Funding; Novartis - Research Funding |
| Kah Poh (Melissa) | Loh | Speaker | Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults | Treatment Options for Older Adults with AML: Recommendations on Low-Dose Cytarabine, Azacitidine, and Decitabine Regimens as Monotherapy or Combinations | Nothing to disclose. |
| Kai | Rejeski | Speaker | Strategies To Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cellular Therapies | Ways to Predict and/or Minimize Hematotoxicity, Infections and Non-Relapse Mortality After Immunotherapy | BMS/CELGENE - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Kite/Gilead - Research Funding; Kite/Gilead - Consultancy (Includes expert testimony) |
| Kalpna | Gupta | Speaker | Ouch-it Hurts: Mechanisms of the Origin, Perception and Evolution of Pain in Sickle Cell Disease | Two Sides of the Same Coin: Sickle Cell Pathobiology and Neural Mechanisms that Evoke, Maintain and Perceive Pain | Honoraria from Novartis and CSL Behring and research grants from Cyclerion, 1910 Genetics, Novartis, Grifols, Zilker LLC, and UCI Foundation. - Honoraria |
| Karandeep | Singh | Speaker | Joint Session: Advancing Hematology Through Artificial Intelligence | Clinical Applications of AI: AI at the Bedside: Real-World Clinical Applications | Google - Consultancy (Includes expert testimony) |
| Karina | Yazdanbakhsh | Speaker | TRIMming the Immune Response: Cutting-Edge Insights into Transfusion-Related Immunomodulation | Special Effects: Recipient Innate Immunity and Transfusion Immunomodulation | Nothing to disclose. |
| Katherine | King | Chair | New Frontiers in Neutrophil Biology | Nothing to disclose. | |
| Kathleen | Freson | Speaker | The Critical Role of Metabolism in Megakaryocyte and Platelet Biology | Altered Metabolisms and Platelet Disorders | Swedish Orphan Biovitrum - Research Funding |
| Kathryn Elizabeth | Webert | Speaker | Decoding the Enigma: Challenges in Classical Hematology Consultations | The Untransfusable Patient | Canadian Blood Services - Current Employment |
| Katja | Weisel | Speaker | Treatment Refinement in Multiple Myeloma | How to Approach the High-Risk Myeloma from Induction through Relapse? | AbbVie - Honoraria; AbbVie - Consultancy (Includes expert testimony); AbbVie - Research Funding; Amgen - Consultancy (Includes expert testimony); Amgen - Honoraria; Amgen - Research Funding; Bristol Myers Squibb - Celgene - Research Funding; Bristol Myers Squibb - Celgene - Consultancy (Includes expert testimony); Bristol Myers Squibb - Celgene - Honoraria; Beigene - Honoraria; Beigene - Consultancy (Includes expert testimony); Takeda - Honoraria; Takeda - Consultancy (Includes expert testimony); Johnson & Johnson - Janssen - Research Funding; Johnson & Johnson - Janssen - Consultancy (Includes expert testimony); Johnson & Johnson - Janssen - Honoraria; Sanofi, - Research Funding; Sanofi, - Consultancy (Includes expert testimony); Sanofi, - Honoraria; Cellcentric - Consultancy (Includes expert testimony); GSK - Research Funding; GSK - Honoraria; GSK - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Karyopharm - Honoraria; Amgen, Bristol Myers Squibb, Janssen-Cilag, GlaxoSmithKline, Adaptive Biotechnologies, Karyopharm Therapeutics, Takeda, Sanofi, AbbVie, GlaxoSmithKline, Novartis, Pfizer, Celgene, Janssen (Inst), Oncopeptides, Roche, Menarini, Stemline Therapeutics, AstraZeneca, BeiGene - Honoraria; Regeneron, - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Novartis - Honoraria; Roche - Consultancy (Includes expert testimony); Roche - Honoraria; Cellcentric - Consultancy (Includes expert testimony); Amgen, Adaptive Biotechnologies, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Cilag, Karyopharm Therapeutics, Sanofi, Takeda, Oncopeptides, Roche, Menarini, Regeneron, AbbVie, BeiGene - Consultancy (Includes expert testimony); Oncopeptides - Honoraria; Oncopeptides - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Pfizer - Honoraria; Menarini Stemline - Consultancy (Includes expert testimony); Menarini Stemline - Honoraria; Bristol Myers Squibb - Honoraria; Bristol Myers Squibb - Consultancy (Includes expert testimony); Adaptive Biotech - Consultancy (Includes expert testimony); Adaptive Biotech - Honoraria |
| Kellie | Machlus | Speaker | Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine | Discovery Based on Population Structure: How to Faithfully Understand and Functionalize Novel Treatments | Nothing to disclose. |
| Koji | Eto | Speaker | The Critical Role of Metabolism in Megakaryocyte and Platelet Biology | Lipid Metabolism, Megakaryocyte Function and Platelet Production | SATAKE MULTIMIX Co. Ltd. - Research Funding; Ebara Corporation - Consultancy (Includes expert testimony); CANON Inc. - Research Funding |
| Konstanze | Döhner | Co-Chair | ASH-EHA Joint Symposium | Abbvie - Consultancy (Includes expert testimony); Jazz - Research Funding; AOP Health - Consultancy (Includes expert testimony); Novartis - Research Funding; GSK - Honoraria; Novartis - Honoraria; AOP Health - Honoraria; Abbvie - Honoraria; GSK - Consultancy (Includes expert testimony); Celgene/BMS - Research Funding; Daiichi Sankyo - Honoraria; Novartis - Consultancy (Includes expert testimony); Celgene/BMS - Consultancy (Includes expert testimony); Servier - Research Funding; Daiichi Sankyo - Consultancy (Includes expert testimony); Celgene/BMS - Honoraria | |
| Kristen | O'Dwyer | Speaker | Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges | Immune Targeting in Ph Negative and Ph Positive B-ALL: Improving Outcomes and Minimizing Chemotherapy in Adult B-ALL | Nothing to disclose. |
| Kristin Ammon | Shimano | Speaker | ASH Clinical Practice Guidelines on Aplastic Anemia | Recommendations for transplant in patients with Aplastic Anemia | Sobi - Research Funding; Sanofi - Research Funding; Novartis - Research Funding |
| Layla | Van Doren | Speaker | ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia | Menstruating individuals: Evidence-based ferritin thresholds | Recordati - Consultancy (Includes expert testimony); Recordati - Honoraria; Pharmacosmos - Consultancy (Includes expert testimony); Pharmacosmos - Honoraria; Bayer - Consultancy (Includes expert testimony) |
| Leif S. | Ludwig | Speaker | Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny | Mitochondrial DNA Mosaicism and Clonality in Human Hematopoiesis | Nothing to disclose. |
| Leslie | Kean | Speaker | Strategies To Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cellular Therapies | New Preclinical and Translational Approaches to Prevent GVHD | Nothing to disclose. |
| Lidia | Gil | Chair | How to Prevent and Manage Infections in Immunocompromised Patients in the Era of Immunotherapy and Growing Antibiotic Resistance | Janssen - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony) | |
| Linus | Voelker | Speaker | The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP | Tailored Treatment of Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura | CSL Vifor - Consultancy (Includes expert testimony); CSL Vifor - Honoraria; Sanofi - Consultancy (Includes expert testimony); Sanofi - Honoraria; Sanofi - Research Funding; Pfizer - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony); Alexion - Honoraria; STADA Arzneimittel AG - Honoraria |
| Lisa | McReynolds | Speaker | JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia | Inherited Susceptibility to Bone Marrow Failure and Leukemia is More Common Than you Think | Nothing to disclose. |
| Luca | Malcovati | Speaker | Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults | Treatment Options for Older Adults with AML and IDH1/IDH2 Mutations: Recommendations on HMA Monotherapy, Combinations with Venetoclax, and Targeted Therapies | Nothing to disclose. |
| Luciano Jose | Costa | Speaker | How I Treat Multiple Myeloma Progression After Upfront Quadruplet Therapy | How I Treat Multiple Myeloma Progression after Upfront Quadruplet Therapy | Adaptive Biotechnologies - Honoraria; Regeneron - Consultancy (Includes expert testimony); Regeneron - Honoraria; Sanofi - Honoraria; Sanofi - Consultancy (Includes expert testimony); Caribou - Consultancy (Includes expert testimony); Caribou - Research Funding; Genentech - Research Funding; Genentech - Consultancy (Includes expert testimony); Genentech - Honoraria; Amgen - Honoraria; Amgen - Research Funding; Amgen - Consultancy (Includes expert testimony); AstraZeneca - Honoraria; AstraZeneca - Research Funding; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Pfizer - Research Funding; BMS - Honoraria; BMS - Consultancy (Includes expert testimony); BMS - Research Funding; AbbVie - Honoraria; AbbVie - Research Funding; AbbVie - Consultancy (Includes expert testimony); Johnson & Johnson - Honoraria; Johnson & Johnson - Consultancy (Includes expert testimony); Johnson & Johnson - Research Funding |
| Luis | Batista | Speaker | Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes | The Connections Between Telomere Biology and Hematopoiesis | Nothing to disclose. |
| Luisa | Iruela-Arispe | Speaker | Thromboinflammation | Endothelial Chemo-Mechanical Signaling in Response to Shear Stress | Nothing to disclose. |
| Lydia | Pecker | Speaker | Our Patient Is Pregnant: Comanaging Obstetric Patients With Complex Hematologic Issues During Their Pregnancy and Delivery | Proactive Management to Improve Outcomes in High-Risk Sickle Cell Disease Pregnancy | Novartis - Research Funding; Afimmune - Research Funding; Novo Nordisk - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony) |
| Maksim | Mamonkin | Speaker | CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias | T-Cell ALL Meets CAR-T: Advancements and Breakthroughs | Curie.bio - Consultancy (Includes expert testimony); Fate Therapeutics - Patents & Royalties; Fate Therapeutics - Research Funding; NKILT Therapeutics - Consultancy (Includes expert testimony); March Biosciences - Research Funding; March Biosciences - Patents & Royalties; March Biosciences - Consultancy (Includes expert testimony); Beam Therapeutics - Patents & Royalties; Galapagos - Ended employment in the past 24 months; Galapagos - Consultancy (Includes expert testimony) |
| Mala | Shanmugam | Chair | Targeting Cancer Metabolism – Innovative Methods to Translation | Nothing to disclose. | |
| Marc | Raaijmakers | Speaker | ASH-EHA Joint Symposium | Review of Menin Inhibitors; Translational Aspects and Clinical Trial | Nothing to disclose. |
| Marco | Ruella Jr | Speaker | The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It | Current Clinical Evidence of Allogeneic Cellular Products Failure and Mechanisms | Guidepoint - Consultancy (Includes expert testimony); Biocartis - Consultancy (Includes expert testimony); viTToria bio - Research Funding; AbClon - Consultancy (Includes expert testimony); ModeX - Consultancy (Includes expert testimony); Lumicks - Research Funding; CURIOX - Research Funding; CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity (Kite), and viTToria biotherapeutics - Patents & Royalties; GLG - Consultancy (Includes expert testimony); AbClon - Research Funding; Acera Bio - Consultancy (Includes expert testimony); Beckman-Coulter - Research Funding; ONI - Research Funding |
| Marco | Ruella Jr | Co-Chair | The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It | Acera Bio - Consultancy (Includes expert testimony); AbClon - Consultancy (Includes expert testimony); CURIOX - Research Funding; Guidepoint - Consultancy (Includes expert testimony); GLG - Consultancy (Includes expert testimony); Biocartis - Consultancy (Includes expert testimony); viTToria bio - Research Funding; Beckman-Coulter - Research Funding; CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity (Kite), and viTToria biotherapeutics - Patents & Royalties; AbClon - Research Funding; ONI - Research Funding; Lumicks - Research Funding; ModeX - Consultancy (Includes expert testimony) | |
| Maria | Gabelli | Speaker | Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why? | Maintenance after CAR-T? Are We There Yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL | novartis - Consultancy (Includes expert testimony) |
| Maria Domenica | Cappellini | Speaker | Hemoglobinopathies and Increased Risk of Venous Thromboembolism | Thalassemia and Hypercoagulability | Vertex - Honoraria; Novo Nordisk - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Sanofi-Genzyme - Honoraria; Sanofi-Genzyme - Consultancy (Includes expert testimony); Bristol Myers Squibb (Celgene) - Honoraria; Bristol Myers Squibb (Celgene) - Consultancy (Includes expert testimony); Pfizer - Honoraria; Silence - Consultancy (Includes expert testimony); Vifor - Consultancy (Includes expert testimony); Agios Pharmaceuticals, Inc. - Honoraria; Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony) |
| Maria R. | Baer | Speaker | Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults | Recommendations for Treatment for Older Adults with AML and FLT3 Mutations | Nothing to disclose. |
| Marie | Bleakley | Speaker | Strategies To Improve Outcomes After Hematopoietic Cell Transplantation and Adoptive Cellular Therapies | Novel Graft Manipulation Strategies - From Bench to Bedside | Promicell - Research Funding; Promicell - Patents & Royalties; Promicell - Current holder of stock options in a privately-held company; Miltenyi Biotec - Consultancy (Includes expert testimony); Miltenyi Biotec - Honoraria; Miltenyi Biotec - Research Funding |
| Marie José | Kersten | Chair | Rare Aggressive B-Cell Lymphomas: Challenge for a Pathologist, Challenge for a Clinician | Mustang Bio - Honoraria; Janssen - Honoraria; Kite/Gilead - Research Funding; Miltenyi - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Adicet Bio - Honoraria; Roche - Honoraria; BeiGene - Honoraria; BMS/Celgene - Consultancy (Includes expert testimony); Galapagos - Honoraria; Mustang Bio - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Kite/Gilead - Honoraria; Adicet Bio - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Miltenyi - Honoraria; BMS - Consultancy (Includes expert testimony); Novartis - Honoraria; BMS/Celgene - Honoraria; AbbVie - Honoraria; BMS - Honoraria; BMS - Consultancy (Includes expert testimony); Galapagos - Consultancy (Includes expert testimony); BMS - Honoraria | |
| Mark | Reding | Speaker | How I Optimize Hemophilia Management: The Role of Novel Treatments | How I Optimize Hemophilia Management: The Role of Novel Treatments | Spark - Honoraria; Spark - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Sanofi - Honoraria; Genentech - Honoraria; Genentech - Consultancy (Includes expert testimony); Biomarin - Research Funding; HEMA Biologics - Honoraria; HEMA Biologics - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Novo Nordisk - Honoraria; Be Biopharma - Research Funding; CSL Behring - Honoraria; CSL Behring - Consultancy (Includes expert testimony); Bayer - Honoraria; Bayer - Consultancy (Includes expert testimony); Bayer - Research Funding; Takeda - Consultancy (Includes expert testimony); Takeda - Honoraria |
| Mark | Reding | Speaker | Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients | New Therapies in Hemophilia: Extend the Half-Life, Bypass, or Rebalance? | Spark - Honoraria; Spark - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Sanofi - Honoraria; Genentech - Honoraria; Genentech - Consultancy (Includes expert testimony); Biomarin - Research Funding; HEMA Biologics - Honoraria; HEMA Biologics - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Novo Nordisk - Honoraria; Be Biopharma - Research Funding; CSL Behring - Honoraria; CSL Behring - Consultancy (Includes expert testimony); Bayer - Honoraria; Bayer - Consultancy (Includes expert testimony); Bayer - Research Funding; Takeda - Consultancy (Includes expert testimony); Takeda - Honoraria |
| Mark | Roschewski | Speaker | Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally | Translating Knowledge about Burkitt Lymphoma Genomics and Microenvironment into Novel Clinical Trials | Nothing to disclose. |
| Mark | Roschewski | Co-Chair | Bridging Translational Science and Clinical Trials to Transform Burkitt Lymphoma Research Globally | Nothing to disclose. | |
| Mark J. | Levis | Speaker | Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why? | Post-HCT Maintenance Therapy for AML: Who, When, Why, How Long? | Astellas - Honoraria; Astellas - Consultancy (Includes expert testimony); Astellas - Research Funding; Menarini - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Syndax - Honoraria; Cullinan Therapeutics - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony); Daiichi-Sankyo - Honoraria; Johnson & Johnson - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony) |
| Mark J. | Levis | Chair | Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why? | Johnson & Johnson - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Cullinan Therapeutics - Consultancy (Includes expert testimony); Astellas - Research Funding; Syndax - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony); Syndax - Honoraria; Menarini - Consultancy (Includes expert testimony); Daiichi-Sankyo - Honoraria; Novartis - Consultancy (Includes expert testimony); Astellas - Honoraria | |
| Markus | Sperandio | Speaker | Thromboinflammation | The Inflammasone: E-selection-Driven Activation | Nothing to disclose. |
| Marlise Rachael | Luskin | Speaker | Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New Efficacious Preparations | Beyond Hypersensitivity: The Gamut of Other Asparaginase Associated Toxicities | Jazz - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AbbVie - Research Funding; Novartis - Research Funding; Novartis - Consultancy (Includes expert testimony); KITE - Consultancy (Includes expert testimony) |
| Marlys | Koschinsky | Speaker | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Lipoprotein(a) and Thrombosis: Insights from Basic and Clinical Science | Novartis - Honoraria; Novartis - Consultancy (Includes expert testimony); Eli Lilly & Co. - Research Funding; Amgen - Research Funding |
| Marta | Derecka | Speaker | Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny | Context Matters: HSC Regeneration in the Cellular Niche | Nothing to disclose. |
| Martin | Rivas | Speaker | Dissecting Enhancer Function in Hematopoietic Development and Disease | Enhancer Function in Lymphoid Development and Lymphoma | Nothing to disclose. |
| Martina | Pigazzi | Speaker | Genomics in Pediatric Acute Leukemia Risk Stratification | Using Genomics to Refine Pediatric AML Risk Stratification | Nothing to disclose. |
| Marvin | Reid | Speaker | ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease | Monitoring Recommendations for Hydroxyurea for SCD | Nothing to disclose. |
| Mary-Elizabeth | Percival | Speaker | Post-SCT Maintenance Strategies in Leukemia: Who, When, and Why? | Peri-transplant Conundrums: Optimizing Maintenance Therapy Using MRD-Directed Approaches | Abbvie - Research Funding; Astex - Research Funding; Pfizer - Research Funding; Biosight - Research Funding; Ascentage - Research Funding; Oncoverity - Research Funding; BMS - Research Funding; Vincerx - Research Funding |
| Mary-Elizabeth | Percival | Chair | ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns | Ascentage - Research Funding; Biosight - Research Funding; BMS - Research Funding; Vincerx - Research Funding; Abbvie - Research Funding; Pfizer - Research Funding; Oncoverity - Research Funding; Astex - Research Funding | |
| Matthew | Vander Heiden | Speaker | Targeting Cancer Metabolism – Innovative Methods to Translation | Nutrient Environment Considerations for Understanding Leukemia Therapy | iTeos Therapeutics - Consultancy (Includes expert testimony); Auron Therapeutics - Consultancy (Includes expert testimony); MPM Capital - Consultancy (Includes expert testimony); Droia Ventures - Consultancy (Includes expert testimony); Pretzel Therapeutics - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Faeth Therapeutics - Consultancy (Includes expert testimony); Lime Therapeutics - Consultancy (Includes expert testimony) |
| May | Daher | Speaker | The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It | Strategies to Reduce Immune Rejection of Off-the-Shelf Cell Therapies | Nothing to disclose. |
| May | Daher | Co-Chair | The Issue of Rejection of Allogeneic Cellular Therapies: Evidence, Mechanisms, and Novel Strategies to Overcome It | Nothing to disclose. | |
| Mazyar | Shadman | Chair | B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders? | Bristol Myers Squibb - Current equity holder in publicly-traded company; Janssen - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); BeOne Medicines Ltd. - Research Funding; AbbVie - Research Funding; Vincerx - Research Funding; Genentech - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Morphosys/Incyte - Research Funding; Nurix - Consultancy (Includes expert testimony); Koi Biotherapeutics - Current holder of stock options in a privately-held company; Morphosys/Incyte - Research Funding; Koi Biotherapeutics - Current holder of stock options in a privately-held company; Bristol Myers Squibb - Consultancy (Includes expert testimony); Genentech, Inc. - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Genmab - Research Funding; Kite Pharma - Consultancy (Includes expert testimony); BeOne Medicines Ltd. - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); AstraZeneca - Research Funding; Pierre Fabre - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Mustang Bio - Consultancy (Includes expert testimony); Genentech, Inc. - Consultancy (Includes expert testimony); Fate therapeutics - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Vincerx - Research Funding; Merck - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Genmab - Research Funding; AbbVie - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); BeiGene - Research Funding; AbbVie - Consultancy (Includes expert testimony); Morphosys/Incyte - Research Funding; Mustang Bio - Research Funding; Fate Therapeutics - Consultancy (Includes expert testimony); AbbVie - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Mustang Bio - Research Funding; Eli Lilly - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); AbbVie - Research Funding; Beigene - Research Funding; BeiGene - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Genentech - Research Funding; Mustang Bio - Research Funding; Morphosys/Incyte - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Genentech - Research Funding; Bristol Myers Squibb (spouse) - Current Employment; AstraZeneca - Research Funding; AstraZeneca - Research Funding; Genmab - Research Funding; Vincerx - Research Funding; Nurix - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Koi Biotherapeutics - Current holder of stock options in a privately-held company; Kite Pharma - Consultancy (Includes expert testimony) | |
| Megan | McNerney | Chair | Dissecting Enhancer Function in Hematopoietic Development and Disease | Nothing to disclose. | |
| Meng | Wang | Speaker | Discovering the Biology of Hematopoiesis Through Studies of Bone Marrow Failure Syndromes | Aldehyde-Induced DNA Damage in HSC Exhaustion and Aging: Lessons from Fanconi Anemia | Nothing to disclose. |
| Merlin | Crossley | Speaker | Flipping the Switch: Fetal Hemoglobin Reactivation for Treating Hemoglobin Disorders – From Mechanism to Therapy | Identifying and Targeting New Regulators of Hemoglobin Switching | CSL Behring Australia - Research Funding |
| Michael | Cole | Speaker | Complementopathies: Modern Diagnosis and Management | Update in the Diagnosis of Complement-Mediated Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome | AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Consultancy (Includes expert testimony); Annexon Inc - Current equity holder in publicly-traded company; Novo Nordisk - Current equity holder in publicly-traded company; Omeros Corporation - Current holder of stock options in a privately-held company; Machaon Diagnostics - Patents & Royalties; Illumina, Inc - Current equity holder in publicly-traded company; Eli Lilly and Company - Current equity holder in publicly-traded company |
| Michael | Milsom | Speaker | JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging | Inflammation and Expansion of Dysregulated Stem Cells | Nothing to disclose. |
| Michael | Pulsipher | Speaker | How I Use NGS in the Pre and Post-HSCT and Cell Therapy Setting | How I Use NGS in the Pre and Post-HSCT and Cell Therapy Setting | Cargo - Consultancy (Includes expert testimony); Sanofi - Honoraria; Mesoblast - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Garuda - Consultancy (Includes expert testimony); Autolus Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotech - Research Funding; Miltenyi - Research Funding |
| Michael R | DeBaun | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Findings from “Sickle Cell Trait Does Not Cause ‘Sickle Cell Crisis’ Leading to Exertion Related Death: A Systematic Review” | Novartis - Consultancy (Includes expert testimony) |
| Michael R | DeBaun | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Novartis - Consultancy (Includes expert testimony) | |
| Michael R | Green | Speaker | Innovative Models of Lymphoma | Utilizing Refined Lymphoma Models for Treatment Studies: Innovations in Syngeneic Transplants, Patient-Derived Xenografts, and Humanized Mouse Model | Shenandoah Therapeutics - Current holder of stock options in a privately-held company; Kite/Gilead - Research Funding; Bristol Myers Squibb - Consultancy (Includes expert testimony); Allogene - Consultancy (Includes expert testimony); Allogene - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Arvinas - Consultancy (Includes expert testimony) |
| Michelle | Sholzberg | Speaker | ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia | Screening and defining iron deficiency in pregnant individuals | Sobi - Honoraria; Octapharma - Research Funding; Octapharma - Honoraria; Pfizer - Honoraria; Pfizer - Research Funding; Werfen - Honoraria; Roche - Honoraria |
| Michelle | Sholzberg | Speaker | Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy | Iron Deficiency/Overload and Its Considerations In Design of Therapeutic Strategies | Sobi - Honoraria; Octapharma - Research Funding; Octapharma - Honoraria; Pfizer - Honoraria; Pfizer - Research Funding; Werfen - Honoraria; Roche - Honoraria |
| Mignon L. | Loh | Speaker | Genomics in Pediatric Acute Leukemia Risk Stratification | Revisiting Novel Genomic Classifiers in the Era of Immunotherapy for Pediatric B-ALL | Jazz Pharmaceuticals - Consultancy (Includes expert testimony) |
| Miguel-Angel | Perales | Speaker | How to Prevent and Manage Infections in Immunocompromised Patients in the Era of Immunotherapy and Growing Antibiotic Resistance | Protection Without Complete Disruption (of the microbiome): Management of Febrile Neutropenia in Immunocompromised Patients in 2025 | Cidara Therapeutics and Sellas Life Sciences - Member DSMB - Honoraria; Adicet, Allogene, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Pierre Fabre, Sanofi, Syncopation, Takeda, VectivBio AG, and Vor Biopharma. - Consultancy (Includes expert testimony); Adicet, Allogene, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Pierre Fabre, Sanofi, Syncopation, Takeda, VectivBio AG, and Vor Biopharma. - Honoraria; Allogene, Genmab, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis - Research Funding; Omeros and OrcaBio - Current holder of stock options in a privately-held company |
| Mikkael | Sekeres | Chair | Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults | BMS - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Keros - Consultancy (Includes expert testimony); BMS - Research Funding; Kurome - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony) | |
| Ming | Lim | Speaker | Update in Hemophilia Across the Lifespan: Novel Therapies/Gene Therapy/Issues in Older Patients | The Ageing Hemophilia Patient | BioMarin - Honoraria; BioMarin - Consultancy (Includes expert testimony); Sanofi - Honoraria; Sanofi - Research Funding; Hema Biologics - Consultancy (Includes expert testimony); Hema Biologics - Honoraria; Bayer - Consultancy (Includes expert testimony); Bayer - Honoraria |
| Mira | Kassouf | Speaker | Dissecting Enhancer Function in Hematopoietic Development and Disease | Multi-partite Enhancer Assembly and Chromatin Architecture | Nothing to disclose. |
| Momoko | Yoshimoto | Speaker | Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease | New Insights Into the Dynamics and Heterogeneity of Waves of Blood Production During Development | Nothing to disclose. |
| Nancy | Gillis | Speaker | JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging | Clonal Hematopoiesis: The Good, the Bad, and the Unknown | Nothing to disclose. |
| Nancy | Speck | Speaker | E. Donnall Thomas Lecture and Prize | Core Binding Factor in Blood Cell Formation and Leukemia | Nothing to disclose. |
| Nardeen | Ayad | Speaker | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von willebrand disease and acquired von willebrand syndrome | Nothing to disclose. |
| Naseema | Gangat | Speaker | Decoding the Enigma: Challenges in Classical Hematology Consultations | JAK2 Wild-Type Erythrocytosis: Concept, Differential Diagnosis, Diagnostic Steps and Treatment Approaches | DISC Medicine - Research Funding; DISC Medicine - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony) |
| Natasha | Szuber | Speaker | ASH Clinical Practice Guidelines on Myelofibrosis | Timing Transplantation and Pre-Transplant Therapy in Myelofibrosis: Recommendations for Optimal Management | Novartis, GSK - Honoraria; Novartis, GSK - Consultancy (Includes expert testimony) |
| Nicolas | Boissel | Speaker | Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma | Where Do Immunotherapies Stand in Management of Acute Leukemia in Adults? | Amgen, Novartis, Jazz Pharamaceuticals, Pfizer, Clinigen, Servier, Gilead, Advesya, Autolus - Consultancy (Includes expert testimony); Amgen, Novartis, Jazz Pharamaceuticals, Pfizer, Clinigen, Servier, Gilead, Advesya, Autolus - Honoraria; Amgen, Incyte, Novartis, Jazz Pharma - Research Funding |
| Nilam | Mangalmurti | Speaker | TRIMming the Immune Response: Cutting-Edge Insights into Transfusion-Related Immunomodulation | Donor Alert: Immunomodulatory Roles of Red Blood Cells | SENTICELL - Current equity holder in private company; SENTICELL - Patents & Royalties; SENTICELL - Research Funding |
| Noopur | Raje | Speaker | Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit | Choosing the Optimal Maintenance Strategy in Multiple Myeloma | BMS - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Sanofi - Research Funding; Kelonia Therapuetics - Consultancy (Includes expert testimony); Pfizer - Research Funding; Pfizer - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Immuneel - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony) |
| Noopur | Raje | Chair | Multiple Myeloma: What Is the Best Induction, Consolidation, and Maintenance for Fit vs. Non-Fit | BMS - Consultancy (Includes expert testimony); Kelonia Therapuetics - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Pfizer - Research Funding; Sanofi - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Immuneel - Consultancy (Includes expert testimony) | |
| Olive | Eckstein | Speaker | Down the Rabbit Hole: An Update on Histiocytic Disorders | Advances in the Diagnosis and Management of Pediatric Langerhans Cell Histiocytosis and Rosai-Dorfman Disease: Therapies, Biomarkers, and Response Assessment | Nothing to disclose. |
| Oliver | Weigert | Speaker | Meet the Scientist: Molecularly Targeted Therapies in Lymphoma | Molecularly Targeted Therapies in Lymphoma | Incyte - Research Funding; Roche - Research Funding |
| Oliver | Weigert | Chair | Innovative Models of Lymphoma | Roche - Research Funding; Incyte - Research Funding | |
| Olujimi | Olaghere | Speaker | To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy | Lived Experience Expert | Nothing to disclose. |
| Omar | Niss | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Leveraging the ASH Research Collaborative SCD Research Network to Understand Underused Disease Modifying Therapies and Updates from Voxelotor?Withdrawal | Pfizer - Ended employment in the past 24 months; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony) |
| Omar | Niss | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Pfizer - Ended employment in the past 24 months; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony) | |
| Paul | La Rosée | Speaker | Down the Rabbit Hole: An Update on Histiocytic Disorders | Hemophagocytic Lymphohistiocytosis: Do We Have a Solution for TMI (Too much Inflammation)? | Incyte - Consultancy (Includes expert testimony); Novartis - Research Funding |
| Paula | James | Speaker | Bleeding Disorder of Unknown Cause—What Do We Know? | Diagnosis of Bleeding Disorder of Unknown Cause: How Many Tests Is Enough To Diagnose BDUC? | Biomarin - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Star/Vega Therapeutics - Consultancy (Includes expert testimony); Pfizer - Research Funding |
| Paula | James | Chair | Bleeding Disorder of Unknown Cause—What Do We Know? | Star/Vega Therapeutics - Consultancy (Includes expert testimony); Biomarin - Consultancy (Includes expert testimony); Pfizer - Research Funding; Roche - Consultancy (Includes expert testimony) | |
| Paulina | Velasquez | Speaker | CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias | Harnessing CAR-T: A New Era in AML Treatment | Nothing to disclose. |
| Peter | Kouides | Speaker | Early Faculty Career Development Session | Developing a Focused Area of Clinical Expertise - Part 1 | Nothing to disclose. |
| Peter | Kouides | Speaker | Early Faculty Career Development Session | Setting Yourself Up for Sustained Success - Panelist 3 | Nothing to disclose. |
| Peter | van Galen | Chair | JOINT SESSION: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging | AbbVie - Research Funding | |
| Peter L. | Gross | Chair | Thromboinflammation | Catalyst Medical Education - Honoraria; Regeneron - Research Funding; Pfizer - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Honoraria; Roche - Consultancy (Includes expert testimony); Leo Pharma - Honoraria | |
| Peter L. | Gross | Co-Chair | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Catalyst Medical Education - Honoraria; Regeneron - Research Funding; Pfizer - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Honoraria; Roche - Consultancy (Includes expert testimony); Leo Pharma - Honoraria | |
| Phillip | Scheinberg | Chair | ASH Clinical Practice Guidelines on Aplastic Anemia | Pfizer, Novartis, AstraZeneca, and Roche - Honoraria; Alnylam, Pfizer - Research Funding; Pfizer, Novartis, AstraZeneca, and Roche - Research Funding; Pfizer, Novartis, AstraZeneca, and Roche - Consultancy (Includes expert testimony) | |
| Pinkal | Desai | Speaker | JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia | Somatic Mutations may Precede Acute Myeloid Leukemia Even Years Before Diagnosis | Rigel - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Servier Pharmaceuticals - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Janssen Research - Research Funding; Kura Oncology - Consultancy (Includes expert testimony); Kura Oncology - Research Funding; BMS - Consultancy (Includes expert testimony); BMS - Research Funding; Enable Life Sciences - Consultancy (Includes expert testimony) |
| R. Coleman | Lindsley | Speaker | JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia | Beyond Malignancy: How Insights from IBMFS Inform Clonal Hematopoiesis Malignancy Risk More Broadly | Jazz Pharmaceuticals - Research Funding; Takeda Oncology - Consultancy (Includes expert testimony); bluebird bio - Consultancy (Includes expert testimony); bluebird bio - Research Funding; Geron Corporation - Consultancy (Includes expert testimony); QIAGEN, LLC - Consultancy (Includes expert testimony); Vertex Pharmaceuticals Incorporated - Consultancy (Includes expert testimony) |
| Rachel E. | Rau | Chair | Asparaginase in ALL/LBL: Balancing the Risk/Benefit of New Efficacious Preparations | Servier pharmaceuticals - Consultancy (Includes expert testimony); Abbvie pharmaceuticals (Spouse) - Ended employment in the past 24 months; Jazz pharmaceuticals - Consultancy (Includes expert testimony); Candid Therapeutics (Spouse) - Current Employment; Jazz pharmaceuticals - Honoraria; Amgen - Honoraria; Abbvie pharmaceuticals (Spouse) - Current holder of stock options in a privately-held company | |
| Rae | Blaylark | Speaker | To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy | Lived Experience Expert | Agios Pharmaceuticals, Inc. - Honoraria |
| Raffaella | Colombatti | Speaker | Sickle Cell Therapies: The Who, What, When, and Where | Optimizing the "Right" Patient Selection for Treatment for Sickle Cell Disease | Novo Nordisk - Consultancy (Includes expert testimony); Vertex - Consultancy (Includes expert testimony); Vertex - Research Funding; Pfizer - Consultancy (Includes expert testimony); Agios - Research Funding; Agios - Consultancy (Includes expert testimony); Addmedica/Theravia - Consultancy (Includes expert testimony) |
| Raffaella | Colombatti | Chair | Sickle Cell Therapies: The Who, What, When, and Where | Pfizer - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Addmedica/Theravia - Consultancy (Includes expert testimony); Agios - Research Funding; Vertex - Consultancy (Includes expert testimony); Vertex - Research Funding; Agios - Consultancy (Includes expert testimony) | |
| Rahma | Warsame | Speaker | Treating Fairly Rounds Lunch | Healthcare Access to Non-English Speaking Populations - Presenter 1 | Takeda - Consultancy (Includes expert testimony); Sanofi - Honoraria; Third bridge - Consultancy (Includes expert testimony) |
| Raj | Kasthuri | Speaker | Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders | What's New in Hereditary Hemorrhagic Telangiectasia? | Terremoto Bio - Consultancy (Includes expert testimony); Crosswalk Therapeutics - Consultancy (Includes expert testimony); Pharmacosmos Therapeutics Inc - Consultancy (Includes expert testimony); Pharmacosmos Therapeutics Inc - Honoraria; Alnylam - Consultancy (Includes expert testimony) |
| Raja | Prince-Eladnani Jr | Speaker | Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins | Decoding the Hemostasis Interactome: A Genetics-Guided Exploration of Blood’s Blueprint | GSK - Research Funding; GSK - Honoraria; GSK - Consultancy (Includes expert testimony); Juno Therapeutics - Research Funding; Sanofi - Research Funding; Menarini Stemline - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); Recordati - Honoraria; Prescient Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Pfizer - Honoraria; 10X Genomics - Research Funding; Celgene - Consultancy (Includes expert testimony); Nektar Therapeutics - Consultancy (Includes expert testimony); AbbVie - Honoraria; AbbVie - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); IQVIA - Consultancy (Includes expert testimony); Differentia Bio - Consultancy (Includes expert testimony); Bristol Myers Squibb - Research Funding; Nektar Therapeutics - Research Funding; Oncopeptides - Honoraria; Oncopeptides - Consultancy (Includes expert testimony); GSK - Honoraria; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Century Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotech - Honoraria; Adaptive Biotech - Consultancy (Includes expert testimony); Eureka Therapeutics - Current holder of stock options in a privately-held company; Fred Hutchinson Cancer Center and licensed to Juno/ Bristol Myers Squibb - Patents & Royalties; Kite, a Gilead Company - Research Funding; Novartis - Consultancy (Includes expert testimony); Adaptive Biotech - Consultancy (Includes expert testimony); Adaptive Biotech - Honoraria; AbbVie - Research Funding; AbbVie - Honoraria; AbbVie - Consultancy (Includes expert testimony); Boxer Capital - Consultancy (Includes expert testimony); Sanofi - Research Funding; AbbVie - Consultancy (Includes expert testimony); AbbVie - Current equity holder in private company; Oncopeptides - Consultancy (Includes expert testimony); Oncopeptides - Honoraria; Celgene - Honoraria; Celgene - Consultancy (Includes expert testimony); Celgene - Research Funding; Bristol-Myers Squibb - Celgene - Honoraria; Bristol-Myers Squibb - Celgene - Research Funding; Bristol-Myers Squibb - Celgene - Consultancy (Includes expert testimony); Caribou Biosciences - Current holder of stock options in a privately-held company; Caribou Biosciences - Consultancy (Includes expert testimony); Janssen - Honoraria; Janssen - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); Recordati - Honoraria; Takeda - Consultancy (Includes expert testimony); Takeda - Honoraria; Genscript - Research Funding; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Johnson & Johnson - Janssen - Consultancy (Includes expert testimony); Johnson & Johnson - Janssen - Honoraria; ArsenalBio - Current holder of stock options in a privately-held company; ArsenalBio - Consultancy (Includes expert testimony); Amgen - Honoraria; Amgen - Consultancy (Includes expert testimony); Sanofi - Research Funding; Johnson & Johnson - Honoraria; Johnson & Johnson - Consultancy (Includes expert testimony); Amgen - Honoraria; Amgen - Consultancy (Includes expert testimony); Celgene - Honoraria; Celgene - Consultancy (Includes expert testimony); Celgene - Research Funding; Adaptive Biotech - Consultancy (Includes expert testimony); Adaptive Biotech - Honoraria; T-CURX - Consultancy (Includes expert testimony); Johnson & Johnson - Janssen - Honoraria; Johnson & Johnson - Janssen - Consultancy (Includes expert testimony); Takeda - Honoraria; Takeda - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Umoja Biopharma - Research Funding; GSK - Honoraria; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Cargo Therapeutics - Consultancy (Includes expert testimony); Cargo Therapeutics - Current holder of stock options in a privately-held company; Gilead Sciences - Research Funding; Myeloid Therapeutics - Current holder of stock options in a privately-held company; Myeloid Therapeutics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Amgen - Honoraria; Bristol Myers Squibb Cell Therapy - Consultancy (Includes expert testimony); Merck Sharp and Dohme - Consultancy (Includes expert testimony); Recordati - Honoraria; Recordati - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Honoraria; Bristol-Myers Squibb - Research Funding |
| Rakhi P. | Naik Jr | Speaker | Hemoglobinopathies and Increased Risk of Venous Thromboembolism | When Sickle Trait Is Not Just Trait: Risk of VTE | Nothing to disclose. |
| Randy | Taplitz | Speaker | How to Prevent and Manage Infections in Immunocompromised Patients in the Era of Immunotherapy and Growing Antibiotic Resistance | Measures to Minimize Infection Risk in Immunocompromised Patients after Cellular Therapies - How, for Whom, for How Long? | Seres - Consultancy (Includes expert testimony); pierre-fabre - Consultancy (Includes expert testimony); karius - Consultancy (Includes expert testimony) |
| Renato | Ostuni | Speaker | New Frontiers in Neutrophil Biology | Single Cell Insights Into Neutrophil Ontogeny | Nothing to disclose. |
| Rinku | Majumder | Chair | Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins | Nothing to disclose. | |
| Rinku | Majumder | Co-Chair | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Nothing to disclose. | |
| Robert | Liem | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | ASH SCD Clinical Guidelines and Implementation Tools in Action | Nothing to disclose. |
| Robert | Liem | Speaker | ASH’s SCD Initiative: 10 Years of Progress and a Look to the Future of Sickle Cell Disease Research and Care | Nothing to disclose. | |
| Rodney | Camire | Speaker | Harnessing The Hemostasis Interactome for Novel Insights and Mechanisms of Coagulation Proteins | Unlocking the Hemostasis Interactome: Activity-Guided Discovery of Blood's Key Connections | Alnylam Pharmaceuticals - Research Funding |
| Ruud | Delwel | Speaker | Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias | Epigenetic Dysregulation Drives Mixed Phenotype Acute Leukemia | Nothing to disclose. |
| Ruud | Delwel | Co-Chair | Transcending Boundaries: Study of Ambiguous Lineage Acute Leukemia Unlocks Mysteries for All Leukemias | Nothing to disclose. | |
| Ryan D. | Cassaday | Speaker | Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges | Sanctuary Sites and Extramedullary Relapses in the Chemo-free World: Insights from Immunotherapies in B-ALL | Amgen - Consultancy (Includes expert testimony); Amgen - Research Funding; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Pfizer - Research Funding; Pepromene Bio - Honoraria; Kite/Gilead - Consultancy (Includes expert testimony); Kite/Gilead - Research Funding; Servier - Consultancy (Includes expert testimony); Servier - Research Funding; Incyte - Research Funding; Autolus - Honoraria; Autolus - Consultancy (Includes expert testimony); Jazz - Consultancy (Includes expert testimony); Jazz - Honoraria |
| Salman | Fazal Jr | Speaker | B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders? | What to Know About Rare B-Cell Malignancies in 2025 | Sanofi - Honoraria; Sanofi - Consultancy (Includes expert testimony); Sumitomo - Research Funding; Abbvie - Consultancy (Includes expert testimony); Abbvie - Honoraria; Abbvie - Research Funding; Blueprint - Consultancy (Includes expert testimony); Blueprint - Honoraria; Kite Pharmaceuticals - Honoraria; Kite Pharmaceuticals - Consultancy (Includes expert testimony); Amgen, Abbvie, BMS, Blueprint, Sobi, Gilead, GSK, Incyte, Janssen, Rigel, Jazz, Karyopharm, Novartis, PharmaEssentia, Sanofi, Servier, Stemline, Taiho, Takeda - Honoraria; Amgen, Abbvie, BMS, Blueprint, Sobi, Gilead, GSK, Incyte, Janssen, Rigel, Jazz, Karyopharm, Novartis, PharmaEssentia, Sanofi, Servier, Stemline, Taiho, Takeda - Consultancy (Includes expert testimony); Taiho Pharmaceuticals - Honoraria; Taiho Pharmaceuticals - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Servier - Honoraria; Kartos Pharmaceuticals - Research Funding; Rigel Pharmaceuticals - Consultancy (Includes expert testimony); Rigel Pharmaceuticals - Honoraria; Glaxosmith Kline - Consultancy (Includes expert testimony); Glaxosmith Kline - Honoraria; Incyte - Honoraria; Incyte - Consultancy (Includes expert testimony); Amgen - Honoraria; Stemline - Honoraria; Stemline - Consultancy (Includes expert testimony); Pharmaessentia - Honoraria; Sobi - Honoraria; Janssen Pharmaceuticals - Consultancy (Includes expert testimony); Janssen Pharmaceuticals - Honoraria; Bristol MyerSquibb - Consultancy (Includes expert testimony); Bristol MyerSquibb - Research Funding; Bristol MyerSquibb - Honoraria; Novartis - Honoraria; Novartis - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Honoraria; Karyopharm - Honoraria |
| Samit | Ghosh | Speaker | Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy | Heme Trafficking and Its Role in Modifying Physiology and Hematopoietic Diseases | Pfizer Inc - Research Funding |
| Sanam | Loghavi | Speaker | Joint Session: Advancing Hematology Through Artificial Intelligence | Diagnostics and Implementation: Smart Diagnostics: Implementing AI in Hematopathology | Ground Truth Labs - Consultancy (Includes expert testimony) |
| Sandhya | Panch | Speaker | How I Treat Clinical Management of Refractory ITP | How I Treat Clinical Management of Refractory ITP | Sobi - Consultancy (Includes expert testimony); Sobi - Research Funding; Recordati - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Novartis - Research Funding; Sanofi - Research Funding; Sanofi - Consultancy (Includes expert testimony) |
| Sandhya | Panch | Speaker | Immune Cytopenias: Addressing Challenges and Advancing Treatments | Refractory ITP: Revisiting Definitions, Diagnostics and Management Paradigms | Sobi - Consultancy (Includes expert testimony); Sobi - Research Funding; Recordati - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Novartis - Research Funding; Sanofi - Research Funding; Sanofi - Consultancy (Includes expert testimony) |
| Sandhya | Panch | Chair | Immune Cytopenias: Addressing Challenges and Advancing Treatments | Novartis - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Novartis - Research Funding; Sanofi - Research Funding; Sanofi - Consultancy (Includes expert testimony); Sobi - Research Funding | |
| Sara | Ghorashian | Speaker | CARs for Kids: Chimeric Antigen Receptor T-cell Therapy for Childhood Leukemias | CAR T-Cell Breakthroughs: Shaping the Future of B-Cell ALL Treatment | Novartis - Honoraria; Autolus Therapeutics - Honoraria; Autolus Therapeutics - Patents & Royalties; Laverock Therapeutics - Consultancy (Includes expert testimony); UCLB - Patents & Royalties |
| Sarah | O'Brien | Speaker | How I Treat Baby on Board: Managing the Hematological Pregnant Patient | How I Treat Baby on Board: Managing the Hematological Pregnant Patient | Nothing to disclose. |
| Sarah | Rutherford | Speaker | Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Molecular Subtypes of DLBCL– Are We Ready to Translate Our Knowledge Into the Change of Treatment Paradigms? | Genentech/Roche - Research Funding; Genmab - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Karyopharm - Research Funding; Karyopharm - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Constellation - Research Funding |
| Sarah | Rutherford | Chair | Now Is the Time to Improve Outcomes in Diffuse Large B-Cell Lymphoma | Genmab - Consultancy (Includes expert testimony); Genentech/Roche - Research Funding; Karyopharm - Research Funding; AbbVie - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Constellation - Research Funding; Pfizer - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony) | |
| Scott | Armstrong | Speaker | ASH-EHA Joint Symposium | Design and Development of Menin Inhibitors, Mechanisms of Action, Clinical Trial Results, and Safety | Janssen - Research Funding; Hyku Therapeutics - Consultancy (Includes expert testimony); Syndax - Research Funding; Nimbus Therapeutics - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony) |
| Seethal | Jacob | Speaker | Sickle Cell Therapies: The Who, What, When, and Where | Optimizing the Right Time to Start Sickle Cell Therapies | Nothing to disclose. |
| Senthil | Sukumar | Speaker | The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP | Challenges and Opportunities in the Long-Term Management of Immune-Mediated TTP | Alexion - Honoraria; Sanofi-Genzyme - Honoraria |
| Senthil | Sukumar | Chair | The Changing Landscape of the Care of Patients With Immune-Mediated and Congenital TTP | Alexion - Honoraria; Sanofi-Genzyme - Honoraria | |
| Shannon | McKinney-Freeman | Chair | Tracing Bloodlines: Decoding Embryonic Waves of Blood Cell Production and Their Contribution to Disease | Nothing to disclose. | |
| Shannon | McWeeney | Speaker | Joint Session: Advancing Hematology Through Artificial Intelligence | General AI: The AI Revolution in Healthcare: From Hype to Real-World Impact | Nothing to disclose. |
| Shannon | McWeeney | Co-Chair | Joint Session: Advancing Hematology Through Artificial Intelligence | Nothing to disclose. | |
| Shannon L. | Maude | Speaker | Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why? | With BiTEs at the Kiddie Table, Where do CARs Come in for Pediatric B-ALL? | Wugen - Research Funding; Wugen - Consultancy (Includes expert testimony); Syndax Pharmaceuticals - Consultancy (Includes expert testimony); Novartis Pharmaceuticals - Patents & Royalties; Novartis Pharmaceuticals - Consultancy (Includes expert testimony); Novartis Pharmaceuticals - Research Funding |
| Shannon L. | Maude | Chair | Navigating Immunotherapies in Pediatric Leukemia and Lymphoma: CAR-Ts, allo-HSCT - How, When, and Why? | Wugen - Research Funding; Novartis Pharmaceuticals - Patents & Royalties; Novartis Pharmaceuticals - Consultancy (Includes expert testimony); Novartis Pharmaceuticals - Research Funding; Wugen - Consultancy (Includes expert testimony); Syndax Pharmaceuticals - Consultancy (Includes expert testimony) | |
| Sharon A | Savage | Co-Chair | JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia | Nothing to disclose. | |
| Sheinei | Alan | Speaker | Sickle Cell Therapies: The Who, What, When, and Where | The Right Patient, the Right Treatment: Tailoring Sickle Cell Disease Care | Pfizer - Honoraria; Pfizer - Research Funding; Agios - Consultancy (Includes expert testimony) |
| Sigbjorn | Berentsen | Speaker | Immune Cytopenias: Addressing Challenges and Advancing Treatments | Diagnosis and Management of Cold Agglutinin Disease | Recordati - Consultancy (Includes expert testimony); HillStar Bio - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony) |
| Sonali | Smith | Speaker | Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma | Emerging Immunotherapy Advances for Non-Hodgkin Lymphomas: Engaging T cells in the Fight | Regeneron - Consultancy (Includes expert testimony); Regeneron - Honoraria; Genmab - Consultancy (Includes expert testimony); Genmab - Honoraria; Genmab - Ended employment in the past 24 months; Foresight Diagnostics - Honoraria; Foresight Diagnostics - Consultancy (Includes expert testimony) |
| Sonali | Smith | Chair | Invasion of the Immunotherapies: Where We Are and Where We Are Going in Leukemia, Lymphoma, and Myeloma | Regeneron - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Genmab - Honoraria; Genmab - Ended employment in the past 24 months; Foresight Diagnostics - Honoraria; Regeneron - Honoraria; Foresight Diagnostics - Consultancy (Includes expert testimony) | |
| Sonata | Jodele | Speaker | Meet The Scientist: Never Go Into Transplant Waters Alone | Never Go into Transplant Water Alone | UniQure - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); US patent - Patents & Royalties; Omeros - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony) |
| Sonata | Jodele | Speaker | Thromboinflammation | Complement On Fire | UniQure - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); US patent - Patents & Royalties; Omeros - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony) |
| Sophie | Zaaijer | Co-Chair | Leveraging Genetic Diversity in Preclinical Discovery to Guide Precision Medicine | Nothing to disclose. | |
| Srinivas | Devarakonda | Co-Chair | Treating Fairly Rounds Lunch | Nothing to disclose. | |
| Stefano | Rivella | Speaker | Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy | Targeting Iron Deficiency/Overload as a Therapeutic Strategy in Treating Hematologic Disease | Disc Medicine - Patents & Royalties; Disc Medicine - Research Funding; Disc Medicine - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony) |
| Stella T | Chou | Speaker | Meet The Scientist: Novel Genetic Markers in Blood Transfusion for Improved Matching | Novel Genetic Markers in Blood Transfusion Type and Cross Match | Nothing to disclose. |
| Stephanie | Halene | Chair | Hematopoiesis in the Golden Years: Aging, Epigenetic Landscapes, and Clonal Destiny | Nothing to disclose. | |
| Sumit | Gupta | Speaker | Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges | The Challenge of De-Intensifying Chemotherapy for Children and Adolescents With B-ALL in The Immunotherapy Era | Amgen - Consultancy (Includes expert testimony); Jazz - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony) |
| Sumit | Gupta | Chair | Frontline Incorporation of Immune Targeting Agents in B-ALL: Triumphs and Challenges | Jazz - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony) | |
| Suzanne | Lentzsch | Speaker | Treatment Refinement in Multiple Myeloma | “Endless” Possibilities and How to Exploit Them? What Is the Optimal Treatment Sequence? | Pfizer, Janssen, GSK, Sanofi, BMS, Karyopharm, Regeneron - Consultancy (Includes expert testimony); Regeneron, PeerView, Clinical Care Options, Aptitude, Medscape, Springer Healthcare - Honoraria; Sanofi, Zentalis - Research Funding |
| Sylvain | Audia | Speaker | Updated ASH Clinical Practice Guidelines on Immune Thrombocytopenia (ITP) in Adults | Should adults with primary ITP requiring initial treatment receive steroids alone or steroids in combination with an additional agent? Recommendations from the ASH Guidelines | Novartis - Honoraria; Novartis - Consultancy (Includes expert testimony); Grifols - Consultancy (Includes expert testimony); Grifols - Honoraria; Sanofy - Honoraria; Sanofy - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); Recordati - Honoraria; Amgen - Honoraria; Argenx - Honoraria; Argenx - Consultancy (Includes expert testimony) |
| Tanya | Siddiqi | Speaker | B-Cell Malignancies Common and Rare: What's New in Chronic Lymphocytic Leukemia and Rare B-Cell Disorders? | The Role of MRD Monitoring and Options for CLL Management in Relapsed/Refractory Disease | Beigene - Honoraria; Gilead - Honoraria; Abbvie - Honoraria; AstraZeneca - Honoraria; BMS - Research Funding; BMS - Honoraria |
| Ted | Wun | Speaker | Hemoglobinopathies and Increased Risk of Venous Thromboembolism | Sickle Cell Disease: Managing Thromboembolism | Pfizer, Inc. - Consultancy (Includes expert testimony); American Society of Hematology - Consultancy (Includes expert testimony); American Society of Hematology - Honoraria; Pfizer, Inc. - Consultancy (Includes expert testimony); Health Resources and Services Administration (HRSA) - Research Funding; National Center for Advancing Translational Science (NCATS)/NIH - Research Funding; California Department of Public Health (CDPH) - Research Funding; California Institute for Regenerative Medicine (CIRM) - Research Funding |
| Ted | Wun | Speaker | How I Treat The Balancing Act of Anticoagulant Management in Hemoglobinopathies | How I Treat the Balancing Act of Anticoagulant Management in Hemoglobinopathies | Pfizer, Inc. - Consultancy (Includes expert testimony); American Society of Hematology - Consultancy (Includes expert testimony); American Society of Hematology - Honoraria; Pfizer, Inc. - Consultancy (Includes expert testimony); Health Resources and Services Administration (HRSA) - Research Funding; National Center for Advancing Translational Science (NCATS)/NIH - Research Funding; California Department of Public Health (CDPH) - Research Funding; California Institute for Regenerative Medicine (CIRM) - Research Funding |
| Ted | Wun | Chair | Hemoglobinopathies and Increased Risk of Venous Thromboembolism | National Center for Advancing Translational Science (NCATS)/NIH - Research Funding; American Society of Hematology - Consultancy (Includes expert testimony); Pfizer, Inc. - Consultancy (Includes expert testimony); Pfizer, Inc. - Consultancy (Includes expert testimony); American Society of Hematology - Honoraria; California Institute for Regenerative Medicine (CIRM) - Research Funding; Health Resources and Services Administration (HRSA) - Research Funding; California Department of Public Health (CDPH) - Research Funding | |
| Theodosia | Kalfa | Speaker | Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics? | Molecular Surprises in Evaluations of Red Cell Disorders | Agios Pharmaceuticals - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Research Funding; Forma Therapeutics / Novo Nordisc - Consultancy (Includes expert testimony); Forma Therapeutics / Novo Nordisc - Research Funding |
| Theodosia | Kalfa | Chair | Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics? | Agios Pharmaceuticals - Consultancy (Includes expert testimony); Forma Therapeutics / Novo Nordisc - Consultancy (Includes expert testimony); Forma Therapeutics / Novo Nordisc - Research Funding; Agios Pharmaceuticals - Research Funding | |
| Thomas | Coates | Speaker | Biology-Based Management of Iron Toxicity and Overload in Hematology Practice | From Treatment to Biology and Back: Managing Iron Overload in Transfused Hemoglobinopathies | Chiesi Farma - Consultancy (Includes expert testimony); Chiesi Farma - Honoraria; Bristol Myers Squibb - Honoraria; Bristol Myers Squibb - Consultancy (Includes expert testimony); Agios Pharma - Honoraria; Agios Pharma - Consultancy (Includes expert testimony) |
| Thomas | Coates | Chair | Biology-Based Management of Iron Toxicity and Overload in Hematology Practice | Chiesi Farma - Honoraria; Bristol Myers Squibb - Honoraria; Agios Pharma - Honoraria; Agios Pharma - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Chiesi Farma - Consultancy (Includes expert testimony) | |
| Thomas | Roades | Speaker | ASH Clinicians in Practice Lunch: Access to Critical Drugs: The Causes, Costs, and Campaigns | The interactions of the pharmaceutical system and how the competing demands of different stakeholders can influence cost and shortages | Nothing to disclose. |
| Thomas L. | Ortel | Speaker | Decoding the Enigma: Challenges in Classical Hematology Consultations | Anticoagulation in Malignancy - The Patient Who Bleeds and Clots Simultaneously | NIH - Research Funding; Stago - Research Funding; UpToDate - Honoraria; Sanofi - Consultancy (Includes expert testimony); CDC - Research Funding; Roche - Consultancy (Includes expert testimony); Instrumentation Laboratory - Consultancy (Includes expert testimony); Instrumentation Laboratory - Research Funding; Werfen - Research Funding; Siemens - Research Funding |
| Timothy | Chlon | Speaker | JOINT SESSION: The Emerging Landscape of Germline Predisposition to Bone Marrow Failure and Leukemia | Defining the Biology of DDX41 | Nothing to disclose. |
| Tirthadipa | Pradhan-Sundd | Speaker | Special Symposium on the Basic Science in Hemostasis and Thrombosis | Blood, Clots, and Scars: Unraveling the Hidden Links Between Coagulation and Liver Cirrhosis | Nothing to disclose. |
| Titilope | Fasipe Jr | Chair | To, Through and Thereafter: Guiding Sickle Cell Disease Patients Considering Gene Therapy | Nothing to disclose. | |
| Tulika | Seth | Chair | Decoding the Enigma: Challenges in Classical Hematology Consultations | Nothing to disclose. | |
| Uma | Borate | Speaker | Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics? | Molecular Approach to Cytopenia and Bone Marrow Failure | Sumitomo - Consultancy (Includes expert testimony); Rigel - Honoraria; Rigel - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); AbbVie - Research Funding; BMS - Consultancy (Includes expert testimony); Blueprint - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); RUNX1 Foundation - Honoraria; Pfizer - Research Funding; Kura Oncology - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Research Funding; Servier Pharmaceuticals - Consultancy (Includes expert testimony); Incyte - Research Funding; Incyte - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony) |
| Usha S | Perepu | Speaker | Early Faculty Career Development Session | Developing a Focused Area of Clinical Expertise - Part 2 | Nothing to disclose. |
| Usha S | Perepu | Speaker | Early Faculty Career Development Session | Setting Yourself Up for Sustained Success - Panelist 4 | Nothing to disclose. |
| Vahid | Afshar-Kharghan | Speaker | Complementopathies: Modern Diagnosis and Management | Long-term Outcome and Management of Complement-Mediated Thrombotic Microangiopathy/aHUS | Nothing to disclose. |
| Venee N. | Tubman | Chair | ASH Clinical Practice Guidelines on Hydroxyurea for Sickle Cell Disease | Vertex Pharmaceuticals - Consultancy (Includes expert testimony) | |
| Veronica | Flood | Speaker | Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders | (Un) Diagnosing von Willebrand Disease | takeda - Consultancy (Includes expert testimony); octapharma - Consultancy (Includes expert testimony); octapharma - Honoraria |
| Veronica | Flood | Chair | Challenges in Diagnosing and Managing Mucocutaneous Bleeding Disorders | octapharma - Consultancy (Includes expert testimony); octapharma - Honoraria; takeda - Consultancy (Includes expert testimony) | |
| Vijay G | Sankaran | Co-Chair | Joint Session: Advancing Hematology Through Artificial Intelligence | Nothing to disclose. | |
| Volker | Hovestadt | Speaker | Epigenomic Frontiers in the Diagnosis of Hematological Malignancies | Long-Read Epigenomic Classification of Acute Leukemia | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts and Ruprecht-Karls-Universität Heidelberg - Patents & Royalties; Syndax Pharmaceuticals - Research Funding; Syndax Pharmaceuticals - Research Funding |
| Wendy | Béguelin | Speaker | Innovative Models of Lymphoma | Genetically Engineered Mouse Models (GEMMs): Dissecting Subtype Specific Biologies | Nothing to disclose. |
| William | Powers | Speaker | Arterial Disease and the Hematologist | Cryptogenic Stroke: Definitions and Management | Nothing to disclose. |
| Wilma | Barcellini | Speaker | Immune Cytopenias: Addressing Challenges and Advancing Treatments | Management of Autoimmune Hemolytic Anemia | Roche - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Alexion - Research Funding; Alexion - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony) |
| Xiao | Peng | Speaker | Molecular Diagnostics for Clinical Classical Hematologists: When to Order, What to Order, What It Means, and When to Refer to Genetics? | Molecular Diagnostics 101: How to Use Genetic Tests in Classical Hematology | Pharming - Consultancy (Includes expert testimony); MedZown - Consultancy (Includes expert testimony); Genesis Therapeutics - Consultancy (Includes expert testimony) |
| Yvette | Yien | Chair | Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy | Nothing to disclose. | |
| Yvonne | Efebera | Co-Chair | Treating Fairly Rounds Lunch | Janssen - Honoraria; Oncopeptides - Honoraria; BMS - Honoraria; Pharmacyclics (via Alliance) - Research Funding; GSK (via Alliance) - Research Funding; Pfizer - Honoraria; Kite - Honoraria; GSK - Honoraria; Orca - Honoraria; Sanofi - Honoraria | |
| Zhuoer | Xie | Speaker | What's New and Current in the World of Bone Marrow Failure | Demystifying the Diagnosis and Management of ICUS, CHIP, and CCUS | Nothing to disclose. |
All relevant financial relationships have been mitigated. Staff planners and all others in control of content have nothing to disclose.
2025 ASH Annual Meeting Planners' Disclosure Information
| Name | Role in Activity | Combined Relationship and Company |
| Maureen Okam Achebe, MD, MPH | Planner | Membership on a Board or Advisory Committee: Fulcrum Therapeutics, Global Blood Therapeutics, Shield Therapeutics, Vertex Pharmaceuticals; Research Funding: Pfizer |
| Bhavana Bhatnagar, DO | Planner | Consultancy: Novartis (End date 7/8/2023); Honoraria: Bristol Meyers Squibb; Daiichi Sankyo; Kite, Servier Pharmaceuticals; Membership on a Board or Advisory Committee: Daiichi Sankyo, Servier Pharma; Speaker's Bureau: Astra Zeneca |
| Ami S. Bhatt, MD, PhD | Planner | Consultancy: biomX, Stylus Medicine; Membership on a Board or Advisory Committee: Cantata Bio, Caribou Biosciences, Stylus Medicine, Patents & Royalties: Stylus Medicine, Stock Options: Stylus Medicine |
| Hetty Eileen Carraway, MD, MBA | Planner | Consultancy: Abbvie, Agios, Sanofi, Taiho, Takeda; Membership on a Board or Advisory Committee: Daiichi Saynko, Genentech, Servier, Speaker's Bureau: Agios, Jazz, Novartis, Sanofi, Stemline |
| Thomas D. Coates, MD | Planner | Consultancy: Agios Pharma, Bristol Meyers Squib, Chiesi Farma, Forma pharma, Honoraria: Agios Pharma, Bristol Meyers Squib, Chiesi Farma, Membership on a Board or Advisory Committee: Agios Pharma, Bristol Meyers Squib, Forma pharma; Patents & Royalties: UpToDate |
| Anna Paulina Dabrowska-Iwanicka, MD | Planner | Honoraria: Abbvie, Gilead |
| Payal C. Desai, MD | Planner | Consultancy: Bluebird Bio (End date - 12/31/2023); Membership on a Board or Advisory Committee: Cheisi; Research Funding: Novartis |
| Courtney D. DiNardo, MD, MSc | Planner | Consultancy: Abbvie, AstraZeneca, BMS, Cleave, Schrodinger, Servier; Honoraria: Astellas, celgene, Daiichi Sankyo, GSK. Loxo, Servier; Membership on a Board or Advisory Committee: Abbvie, AstraZeneca, GenMaB, GSK, Servier, Research Funding: Astex, BMS, Celgene, Cleave, Daiichi Sankyo, Foghorn, Loxo, Schrodinger, Servier |
| Saar Gill, MD, PhD | Planner | Membership on a Board or Advisory Committee: Carisma Therapeutics (End Date 1/1/24), Currus, Interius Biotherapeutics, Mission Bio, NKILT Therapeutics; Patents and Royalties: Carisma Therapeutics, Gilead, Interius Biotherapeutics; Research Funding: Asher Bio, Danaher, Interius Biotherapeutics, Vor Bio; Stock Options (Private company):Interius Biotherapeutics Stock Ownership: Carisma Therapeutics |
| Torsten Haferlach, MD, PhD | Planner | Equity Ownership: MLL Munich Leukemia Laboratory; Honoraria: BMS, Jazz, MLL Munich Leukemia Laboratory, Pfizer |
| Michael Jaglal, MD | Planner | Nothing to disclose |
| Judith Kleinerman, MD | Planner/Planning Decision Reviewer | Nothing to disclose |
| Mary Ann Knovich, MD | Planner/Planning Decision Reviewer | Nothing to disclose |
| Alice D. Ma, MD | Planner | Honoraria: Takeda |
| Deepa Manwani, MBBS | Planner | Consultancy: Editas, GBT, Novartis, Pfizer; Membership on a Board or Advisory Committee: Editas |
| Marshall A. Mazepa, MD | Planner/Planning Decision Reviewer | Nothing to disclose |
| Lori S. Muffly, MD | Planner | Consultancy: Astellas (End date 1/1/24), Autolus, Kite, Pfizer; Honoraria: Adaptive; Membership on a Board or Advisory Committee: Amgen, Autolus, Bristol Myers Squibb, Cargo, CTI Biopharma, Incyte, kite, Medexus, Pfizer, Vor. Research Funding: Adaptive, Astellas, Jasper, Kite, Vor, Wugen |
| Esther A. Obeng, MD, PhD | Planner | Nothing to disclose |
| Betty Pace, MD | Planner | Consultancy: AkiraBio Inc (End Date 12/31/2024); Stock Options AkiraBio, Inc |
| Rachel E. Rau | Planner | Consultancy: Jazz Pharmaceuticals, Servier pharmaceuticals Honoraria: Amgen, Jazz pharmaceuticals |
| Vijay G. Sankaran | Planner | Consultancy: Cellarity, Ensoma |
| Tulika Seth, MD, MBBS | Planner | Nothing to Disclose |
| Jay Spiegel | Planner | Consultancy: Caribou Biosciences, Kite Pharma |
| Rahma Warsame, MD | Planner/Planning Decision Reviewer | Nothing to disclose |
| Robert Zeiser, MD | Planner | Consultancy: Incyte, Novartis, Sanofi; Honoraria: Mallinckroth, Neovii, Research Funding::Novartis |
| Sumithira Vasu, MD, MBBS | Planner | Membership on a Board or Advisory Committee: Johnson and Johnson (End date - 12/31/23), Omeros (End Date - 12/31/24), Research Funding: Kiadis/Sanofi (End date - 12-31-24), Neximmune (End date - 12/31/23) |
All relevant financial relationships have been mitigated. Staff planners and other individuals in control of content have nothing to disclose.